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ABSTRACT 
Elizabeth T. Jensen: Pharmacologic sex hormone use before and in early pregnancy in 
relation to birth and early childhood anthropometric outcomes 
(Under the direction of Julie Daniels) 
 
Objective: Possible adverse effects resulting from use of hormonal contraceptives 
have been studied extensively, yet few studies have been conducted evaluating the 
association between hormonal contraceptive use and offspring anthropometric indices and 
most studies have been unable to explore formulation-specific effects.  
Methods: Using data from a large, prospective pregnancy cohort study (n=44,734), 
with linkage to a national prescription registry, we evaluated the association between use of 
hormonal contraceptives (defined from dispensed prescription data) prior to and in early 
pregnancy (characterized by last date of use relative to conception, 12 - >4 months before, 4 
- >1 months before, 1 - > 0 months before, and 0-12 weeks after) and preterm birth, small 
for gestational age, and overweight or obesity at age 3.  We characterized use of a 
hormonal contraception by type (combination oral, progestin-only oral, vaginal ring, 
transdermal, and injectable) and specific progestin component. 
Results: We observed a positive association between use of a combination oral 
contraceptive and preterm birth for all exposure periods (adjusted OR: 1.21, 95% CI: 1.04, 
1.41 for exposure within 12 months before conception).  Generally, use of other types of 
hormonal contraception was not associated with preterm birth.  Overall, use of a hormonal 
contraceptive was unrelated to small for gestational age.  Evaluation of the association by 
progestin type identified variation by progestin formulation. We observed a weak, inverse 
association between early pregnancy use of a combination oral contraceptive and offspring 
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overweight or obesity at age 3 (adjusted OR: 0.75, 95% CI: 0.53, 1.08) and a weak, positive 
association with use of a progestin-only oral contraceptive in early pregnancy (adjusted OR: 
1.26, 95% CI: 0.79, 2.02).  Observed associations were robust to sensitivity analyses.    
Conclusion: Hormonal contraceptive use prior to and in early pregnancy may be 
associated with preterm birth and offspring overweight.  The association appears contingent 
upon the specific type or progestin component used.  The potential for confounding by 
indication cannot be ruled out.  Larger studies using population-based pregnancy cohort 
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INTRODUCTION   
 
Worldwide, the prevalence of childhood overweight and obesity increased from 4.2 
percent in 1990 to 6.7 percent in 2010.(1-3)  Children who are overweight or obese are 
more likely to be overweight or obese into adulthood and to suffer from obesity-precipitated 
morbidity and mortality.  Experiments on animals have shown a positive association 
between exogenous estrogen exposure in utero and metabolic disruption in the offspring, 
including offspring development of overweight or obesity.  These studies generally address 
the risk of low-dose exposure to environmental sources of estrogen-mimicking compounds, 
including exposure in early gestation prior to uterine implantation. Animal data have 
demonstrated that exposure to environmental toxicants with estrogen-like effects result in 
alterations to both follicular development and embryonic quiescence.  Experimental data 
also suggests that the maternal metabolic environment may alter follicular and embryonic 
development.  These alterations may influence embryonic viability and adiposity in later life.  
Pharmacologic sex hormones such as hormonal contraceptives have metabolic effects in 
women.  Hormonal contraceptives contain estrogenic and progestogenic compounds and 
may influence follicular development and embryonic development directly or through altered 
maternal metabolism. 
The potential risks of exogenous sex hormone exposure on offspring overweight or 
obesity are difficult to assess in human populations.  Most cohort studies lack power to 
assess the influence of exogenous sex hormone exposure during pregnancy on offspring 
obesity.  The Norwegian Mother and Child Cohort Study (MoBa), a prospective, population-
based cohort study conducted by the Norwegian Institute of Public Health, offers an unusual
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opportunity to assess the influence of in utero exposure to exogenous sex hormones on 
birth outcomes and childhood overweight or obesity.  In the present study we assessed the 
association of exogenous sex hormone exposure during follicular development and early 
embryonic development on anthropometric measures at birth and at age 36 months.  
Specifically, we assessed the association between exposures within the discrete periods of 
12 months before conception, 4 months before conception, 1 month before conception, and 
within 12 weeks after conception, on offspring weight for gestational age, gestational length, 
and Body Mass Index (BMI) at 36 months of age. 
Study Aims: 
Aim 1: Evaluate the potential association between hormonal contraceptive use and 
birth outcomes, including weight for gestational age, small for gestational age, gestational 
length, and preterm birth 
Aim 2: Evaluate the potential association between hormonal contraceptive use and 
offspring body mass index, overweight or obesity at 36 months of age 
In the MoBa cohort, questionnaires are self-administered and offspring height and 
weight are parent-reported.  Exposure to pharmaceutical hormones was assessed through 
linkage to the Norwegian Prescription Database (NorPD). Generalized linear regression 
models were used to model the association between sex hormone exposure(s) and study 
outcomes.  Sensitivity analyses were conducted to inform the robustness of study results 
given the potential for confounding and selection bias.   
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CHAPTER 1: SIGNIFICANCE AND INNOVATION 
 
1.1 Significance 
Worldwide, as of 2010, an estimated 43 million children were overweight or obese.  
The prevalence of childhood overweight and obesity has increased from 4.2 percent in 1990 
to 6.7 percent in 2010.(1-3)  In Norway, where the present study took place, it is estimated 
that 17% of school-aged children are overweight or obese.(4)  Children who are overweight 
or obese are more likely to be overweight or obese in adulthood and to suffer from obesity-
precipitated morbidity and mortality.(5, 6)  Extensive efforts have been made to stem the 
rising tide of obesity, primarily in the form of interventions targeted to increase physical 
activity and improve dietary behaviors of populations at risk of or already overweight or 
obese.  These efforts have met with limited success, suggesting that either diet and exercise 
patterns cannot fully explain the increase in overweight and obese or the interventions 
themselves are inadequate in modifying individual behaviors.  It is likely that the etiology of 
overweight and obese is extremely complex and no single pathway exists in the 
development of overweight or obese.  There has been increasing interest in developmental 
origins of disease, including development of overweight and obese.  The proposed study 
explored whether exposure to exogenous sex hormones, specifically use of hormonal 
contraceptives, was associated with altered birth and early childhood anthropometric 
indicators.  
Biological rationale 
The biological mechanism for altered growth of the fetus and development of 
overweight or obesity as a result of exogenous sex hormone exposure may be rooted in 
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insults incurred in very early life, in the first few days post-conception or possibly even 
before conception.  The normal hormonal milieu in menstruating women and in early 
pregnancy serves as a framework for understanding the possible effects of hormonal 
contraceptives on offspring outcomes. The menstrual cycle and follicular development  
In a typical menstrual cycle, the hypothalamus secretes gonadotropin-releasing 
hormones (GnRH), which in turn stimulates and modulates pituitary secretion of 
gonadotropins (follicle stimulating hormone and luteinizing hormone).  Ovarian follicles 
respond to the gonadotropins by synthesizing estradiol and progesterone.  Estradiol 
regulates LH secretion in a complex fashion that leads to the LH surge at midcycle.  At the 
midpoint of the menstrual cycle, LH surges and stimulates ovulation.  Following ovulation, 
the follicle converts to a corpus luteum and begins secreting progesterone.  The 
progesterone level peaks 3-4 days after ovulation and remains elevated until about 14 days 
post-ovulation.  If pregnancy occurs, human chorionic gonadotropin sustains the corpus 
luteum for 6-7 weeks.  If pregnancy does not occur, the corpus luteum decreases in volume 
and production of progesterone diminishes and estradiol, progesterone, and LH reach their 
lowest levels in the cycle.  In response, FSH production increases and a new menstrual 
cycle begins.  The increase in FSH promotes maturation of ovarian follicles by binding to 
receptors in the granulosa cells surrounding the oocytes.  This in turn promotes cell 
differentiation and mitosis and an increase in the number of granulosa cells.  These 
granulosa cells then secrete the estradiol that leads to suppression of FSH and secretion of 
LH in the pituitary gland.(7)  
Although selection of a dominant follicle is initiated within the span of the menstrual 
cycle, follicular and oocyte development begin much earlier.  Recruitment of cohorts of 
primordial follicles into the growing pool of oocytes is an ongoing process that functions 
independently of gonadotropins.  It is estimated that the oocyte destined to ovulate is 
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recruited 10-12 months prior to ovulation.  Intra-ovarian signaling molecules regulate 
follicle/oocyte growth.  Specifically, signaling molecules generated by growing follicles act on 
non-growing follicles to suppress their growth.  This complex milieu is fine-tuned to support a 
restricted number of follicles to grow and from which the oocyte destined to ovulate will be 
chosen while the others undergo atresia.  These same regulatory signals ensure that most 
primordial follicles do not grow and are thereby reserved for future recruitment.(8)  In animal 
models, the recruitment of a follicle for selection as a dominant follicle and oocyte 
maturation has been influenced by exposure to endocrine disrupting chemicals.(9-13)  
Endogenous sex hormones in early pregnancy 
In a normal pregnancy, the fertilized oocyte implants in the endometrium of the 
uterus and begins secreting human chorionic gonadotropin (hCG).  HCG sustains the 
corpus luteum for an additional 6-7 weeks which provides sustained release of 
progesterone.(7) At about 6 weeks gestation the placenta takes over production of 
progesterone and endogenous levels of both progesterone and estradiol increase 
dramatically (Figure 1.1).(14) 
   




Progesterone is the most abundant and potent progestin in humans.  Other, less 
active forms of progestin include 17α-hydroxyprogesterone and 10α-hydroxyprogesterone.  
17β- estradiol is the most abundant and biologically active form of estrogen in humans.  
Estriol and estrone are less abundant and less active forms of estrogen.(15) Early 
pregnancy progesterone levels range from 10-35 ng/mL through about 10 weeks of 
gestation at which point levels rise through the remainder of pregnancy, peaking at a 
concentration of 100-300 ng/mL.  Concentration of 17β-estradiol gradually increases 
throughout pregnancy, from conception onward, with levels at conception less than 0.4 
ng/mL, increasing to a range of 6-30 ng/mL at term.(16) 
Hormonal contraception and the menstrual cycle 
Hormonal contraceptives are an exogenous, pharmacologic source of sex hormones 
designed to prevent pregnancy.  The primary mechanism by which pregnancy is prevented 
when using hormonal contraceptives is through suppression of GnRH release from the 
hypothalamus with resulting suppression of pituitary release of gonadotropins (described 
above).  In preventing release of gonadotropins, the gonadotropin-dependent growth of the 
follicles from which the dominant follicle would be selected is inhibited and thus ovulation is 
prevented.  Progestin-only contraceptive formulations are less reliable in their suppression 
of ovulation.  About 40% of women will ovulate while taking progestin-only contraceptives.  
Progestin prevents conception through suppression of LH release, thickening cervical 
mucus (making it impermeable to sperm), altering fallopian tube peristalsis, and altering the 
endometrium (making it non-receptive to implantation).  The estrogenic component of 
combination contraceptives, which contain both estrogenic and progestogenic components, 
suppresses FSH secretion, which prevents selection and development of a dominant follicle.  
The estrogenic component also increases the effect of the progestin component by 
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increasing the number of intracellular progesterone receptors, thus increasing the 
opportunity for progesterone binding and subsequent signaling.(7, 17) 
Metabolic effects of hormonal contraceptives 
Oral contraceptives can alter lipid profiles, specifically increasing very low-density 
lipoprotein cholesterol levels and increasing total triglycerides.(18-20)  Oral contraceptives 
also increase blood glucose levels, increase insulin levels, increase plasma cortisol levels 
(20) and induce a state of insulin resistance.(18, 19)  Interestingly, some of the metabolic 
changes elicited by hormonal contraceptives are similar to the metabolic changes that occur 
in women who are overweight or obese, specifically increased total cholesterol (21) and 
increased insulin resistance.(22)  These effects have been the source of debate on the 
safety of oral contraceptives, particularly for women at risk of venous thrombosis and 
particularly for combination formulation oral contraceptives with an estrogen component.  
Oral contraceptives are contraindicated for some women.  For example, oral contraceptive 
use is strictly contraindicated in women over the age of 35 who smoke.(7)   
Metabolic disruption of early embryo development 
Hormonal contraceptive-induced changes in maternal metabolic milieu may alter 
early embryonic development.  In early embryogenesis, alterations in the environment of the 
embryo, before implantation has occurred, may result in increased metabolic activity of the 
embryo.  This increased metabolic activity may lead to embryonic demise.(23, 24)  In more 
subtle alterations of the environment, it may lead to altered growth and development of the 
embryo.(25)   
The “quiet embryo hypothesis” suggests that metabolically quiet embryos, or 
embryos with less active mitochondria, are more viable and that a loss of “quietness” can 
result in reactive oxygen species (oxidative stress) that can damage DNA.(23, 24, 26)  
There are animal model studies that support this hypothesis.  In one study of mouse 
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embryos, periconception exposure to a high protein diet increased embryonic mitochondrial 
activity and increased embryonic levels of reactive oxygen species.(27)  In another study of 
the effects of maternal obesity, obese mice, relative to normal weight mice, had an 
increased number of apoptotic follicles in the ovaries, smaller and fewer oocytes, and 
smaller pups at birth.  By 13 weeks post-birth, these pups were significantly larger than pups 
born to normal weight mice.(28)  Rapid growth, following suppressed growth in early 
development, may contribute to the subsequent higher weight of offspring born to exposed 
mice.   
Dose and biological activity  
Assessing the level of exposure incurred, whether through pharmacologic or 
environmental sources, is highly complex.  Table 1.1 describes exposure by the amount of 
agent ingested orally. 
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Table 1.1. Potential daily human exposure to various estrogens 




mestranol or ethinyl estradiol 
Oral 20-50 Hardman et al. 1996 
Hormone replacement 
therapy, ethinyl estradiol 
Oral 50-200 Scott et al. 1991 




Dieckmann et al.1953; Wilcox et al. 1995 
Bisphenol A in food cans Oral 6.3 Howe and Borodinsky 1998; Howe et al. 
1998; Wingender et al. 1998 
Bisphenol A in beverage 
containers 
Oral <0.75 Brotons et al. 1995; Howe and 
Borodinsky 1998; Howe et al. 1998; 
Wingender et al. 1998 
Bisphenol A in dental 
sealant 
Oral 90-931 in 
first hr 
Olea et al. 1996 
Nonylphenol in river water Oral 0.7 Weeks et al. 1996 
DDT in total diet Oral 0.01 Gunderson 1995 
PCBs in total diet Oral 0.002 Gunderson 1995 
Phytoestrogen,100 g of 
wheat 
Oral 200 Verdeal and Ryan 1979 
Phytoestrogen, total 
bioflavonoids 
Oral 1,000,000 Kuhnau 1976 
Source: Commission on Life Sciences. Hormonally active agents in the environment, National Academies Press; 
1999.(29)   
However, simply evaluating exposure does not take into consideration the biological 
availability and subsequent action of the substance once it is absorbed.  There are many 
factors that influence the biological effects that these exposures may have on the host.  
Endogenous steroid hormones bind their receptors and the hormone-receptor complex then 
either stimulates or represses gene transcription.  Hormonally active agents can have similar 
effects or they can interfere with endogenous hormones, for example, by binding the 
receptor but not activating gene transcription as efficiently as the endogenous hormone.  
Different agents have different affinities for binding with sex hormone receptors and their 
affinity for binding is influenced by their chemical properties and by the environment of the 
cell, tissue, or organ in which the receptors are located.   
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Biological activity is also influenced by the half-life of the agent.  An agent with a low 
binding affinity, but longer half-life, may have stronger biological influence than an agent 
with higher affinity and shorter half-life.(29)  The binding affinity of ethinyl estradiol, the 
synthetic estrogen in most oral contraceptives, is similar to that of 17β-estradiol, the most 
biologically active form of endogenous estrogen.(30)  Environmental sources of estrogen-
like compounds have lower relative binding affinities for the estrogen receptor (Table 
1.2).(31)  









17β - Estradiol 
 
100.000 2.00 Strong 
Estrone 7.309 0.86 Strong 




399.556 2.60 Strong 
Ethinyl estradiol 190.063 2.28 Strong 




0.008 -2.11 weak 
Bisphenol B 0.086 -1.07 moderate 
o,p-DDT 0.001 -2.85 weak 
2,3,4,5 – Tetrachloro-4-biphenylol (a PCB) 0.228 -0.64 moderate 
*Adapted from Blair et al., 2000 (31)  
†Relative Binding Affinity - defined as IC50 for 17β-estradiol ÷ IC50 of competitor, where IC50 is the molar 
concentration at which there is 50% inhibition of estradiol binding 
 
Some studies have suggested that there is a non-monotonic association between 
environmental sources of hormone-like exposures and adverse effects in offspring. These 
studies generally assess the association between very high levels of exposure.(32)  The 
level of exposure in the present study of sex hormone exposure, while significantly greater 
than exposures incurred environmentally, are likely low-dose exposures relative to the 
exposures that demonstrate non-monotonic effects.   
The dose incurred through hormonal contraceptives, as compared to environmental 
agents, is likely higher than environmental sources of estrogen-like compounds, but not as 
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high as levels encountered through endogenous levels of circulating hormones.  The tables 
below (Tables 1.3 and 1.4) describe the mean serum concentrations of 17β-estradiol and 
progesterone in pregnant and non-pregnant, menstruating women, and ethinyl estradiol and 
progestin concentrations in women using oral contraceptives. 
Table 1.3. Mean and peak serum concentrations of 17β-estradiol and 
progesterone over one menstrual cycle and during early pregnancy  














Early pregnancy‡ 1640 49  
*Adapted from Stricker et al., 2006 (33) 
†Peak estradiol concentration for women spontaneously ovulating is mid-cyle, one day prior to the LH peak, for 
progesterone the peak concentration is post-ovulation, in the mid-luteal phase 
‡At 5 weeks gestation (34) 
 
Table 1.4. Maximum area under the curve (AUC) and mean daily serum 
concentrations of ethinyl estradiol and progestin concentrations for two oral 
contraceptives*  
Formulation Ethinyl estradiol (pmol/L) Progestin (nmol/L) 
90 mcg levonorgestrel and  
20 mcg ethinyl estradiol 
maximum 
AUC0-24 hours 












1mg norethindrone acetate and 
35 mcg ethinyl estradiol 
maximum 
AUC0-24 hours 













*Estimated from drug label data(35) 
The estimated mean daily serum concentration of ethinyl estradiol is ~30-45% of the 
endogenous estradiol concentration but may have stronger binding affinity to the estrogen 
receptor (Table 1.2) than endogenous estradiol.  Other factors that may influence the 
biological activity of the oral contraceptives are the half-life and drug bioavailability.  Unlike 
17β-estradiol, ethinyl estradiol does not bind to sex hormone binding globulin (SHBG) but is 
primarily bound to albumin.(35)  These differences further illustrate how exogenous 
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estrogenic agents of hormonal contraceptives are imperfect in their approximation of 
endogenous 17β-estradiol. 
Summary of existing literature 
Experiments on animals have shown a positive association between exogenous 
perinatal estrogen exposure and metabolic disruption in the offspring, including offspring 
development of overweight or obesity.  These studies generally address the risk of low-dose 
exposure to environmental sources of estrogen-mimicking compounds.(36-38)  For 
example, neonatal (days 1-5) exposure to 1mg/kg diethylstilbestrol (DES) in mice resulted in 
an initial period of depressed growth, followed by increasing adiposity through 4 months of 
age.(39)  
Similarly, in another animal model of sows administered varying doses of 17β -
estradiol during pregnancy, a period of depressed growth in the offspring, followed by 
increased growth was observed.  At slaughter, ~60 days of age, the proportion of fat mass in 
piglets from exposed sows was significantly higher than in male piglets from control 
sows.(40)  At least one study, in a mouse model, found an association between exposure in 
early gestation, prior to uterine implantation, and subsequent offspring obesity.(41) 
With respect to use of hormonal contraceptives, there are no published studies to 
date on long-term effects of hormonal contraceptives on offspring overweight or obesity.  
Although the long-term effects of oral contraceptives during pregnancy on offspring 
morbidity or mortality are unknown, there is some evidence that oral contraceptives may 
increase the risk of some birth defects.(42)  Several human studies have explored the 
association between the use of hormonal contraceptives prior to or after conception on 
adverse offspring outcomes at birth, with no clear indication as to whether use confers 
increased risk.  A few studies suggest that associations with adverse outcomes were 
strongest when exposure was near or at the time of 
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focused on oral contraceptive use before pregnancy.  Two studies specifically assessed 
associations between use in early pregnancy and adverse birth outcomes, but the sample 
sizes were small.(43, 44)  None of the studies have explored differences by progestin-only 
versus combination formulation contraceptives.  A summary of these studies is below (Table 
1.5). 
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Table 1.5. Summary of literature for oral contraceptive (OC) use and selected 
birth outcomes  
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for OC users (n~1,800 
for planned and n=39 








study of women 
recruited 
through family 
planning clinics  
9.9% LBW in parous 
unplanned OC user 
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al. BJOG 
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and LBW for users in 
0-30 day window -- OR 
1.61 (1.01, 2.55) and 
increased risk of LBW 




There is evidence to support a mode of action for exogenous sex hormone exposure 
in causing overweight and obesity in animal models, possibly through metabolic disruption in 
early embryonic development, but human epidemiologic evidence was nonexistent.  Thus, 
this research took the next step, applying epidemiologic approaches to determine if there is 
evidence that exogenous sex hormones contribute to the increased prevalence of 
overweight and obesity.  Environmental sources of exogenous hormone exposures are 
ubiquitous, but confer extremely low-dose exposures.  An epidemiologic study of the 
association resulting from higher dose, pharmaceutical-based use of sex hormones in early 
pregnancy offered a cost efficient means for studying the potential for harm resulting 
through lower level exposures.   
Few children are exposed to pharmacologic sources of sex hormones in early 
pregnancy.  Although the number of infants conceived through assisted reproductive 
methods (ART) is increasing, in the United States only 1 percent (2006) of infants born 
result from use of ART methods.(51)  The incidence of oral contraceptive failure varies by 
country(52) but is estimated to be about 9 percent in the United States.(53, 54)  However, of 
those pregnancies resulting from failed oral contraceptives, many will be intentionally 
terminated in early pregnancy,(53) further reducing the number of infants whereby effects of 
exogenous sex hormones can be studied.  Consequently, most observational studies are 
underpowered for assessing the association of pharmacologic sex hormone exposure in 
utero and offspring overweight or obesity.  Large cohort studies offer the opportunity to 
study exposures that are of relatively low incidence, while increasing the potential that there 
will be sufficient power for adjustment for possible confounders or assessment of possible 
effect modifiers.   
Multiple scientific areas of inquiry may be informed by the findings of this study.  
Evidence of increased risk for offspring overweight or obesity from early, higher (relative to 
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environmental sources) dose exposures to sex hormones would lend credence to the 
hypothesis that low doses, such as those encountered through environmental toxicants, 
increase risk.  This study also yields etiologic clues into the disparity in health outcomes, 
such as elevated lipid profiles, increased blood pressure, lower birth weight, and shorter 
gestation,(55, 56) for infants conceived through sex hormone-based assistive reproductive 
treatments.  Most importantly, this epidemiologic study contributes to an improved 
understanding of one mechanism for the early fetal origins of overweight and obesity upon 
which future studies and, ultimately, interventions can be built. 
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CHAPTER 2: APPROACH 
 
2.1 Study design  
This study was a secondary analysis of a large, population-based, prospective cohort 
study, whereby we assessed the association between pharmacologic sex hormone use in 
early pregnancy and birth outcomes, including small for gestational age, weight for 
gestational age, preterm birth, and gestational length, and altered weight for height status at 
36 months of age, including BMI and overweight or obesity.   
2.2 Study population  
The Norwegian Mother and Child Cohort Study (MoBa) is a prospective, population-
based pregnancy cohort study conducted by the Norwegian Institute of Public Health.(57, 
58)  The MoBa cohort dataset was the primary source of data for this study and was used to 
define many of the study variables, either in conjunction with other data sources or in 
isolation.  MoBa study participants were recruited from 1999 through 2008 through mailed 
invitation and enrolled at the routine ultrasound examination offered to all pregnant women 
in Norway at 17-19 weeks of gestation.  Approximately 42 percent of all pregnant women in 
Norway, who reached at least 16 weeks of gestation, were invited to participate in the study.  
Of these, about 40 percent consented to participate.  Informed consent was obtained from 
each MoBa participant upon recruitment.  The Regional Committee for Medical Research 
Ethics in Southeastern Norway approved the study.  At enrollment, participants were asked 
to provide a blood plasma specimen and to complete an initial, self-administered 
questionnaire to collect demographic characteristics, reproductive health history, disease 
and medication history, lifestyle factors, and socioeconomic status.  Follow-up is conducted
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by self-administered questionnaires at regular intervals and by linkage to national health 
registries.  The cohort includes over 108,000 children, over 90,000 mothers, and 71,000 
fathers.  To date, there are approximately 40,000 children with completed 36-month 
questionnaires.  
The Medical Birth Registry of Norway (MBRN) data was used in this study to define 
study outcomes (Aim 1) and to estimate the date of conception.  MBRN data are available in 
the MoBa cohort database, through linkage of MoBa data with the MBRN, made possible by 
the unique personal identifier assigned to all Norwegians.  All data in MBRN are collected on 
a standardized birth notification form completed by the midwife or physician attending the 
birth.  Compared to the source population of all pregnancies in Norway, the MoBa cohort is 
slightly healthier (Table 2.1). 
Table 2.1: Characteristics of 26,777 participants in MoBa and 226,057 births in 
Norway 2000–2003* 



































































*Source: Magnus et al. 2006(57) 
The Norwegian Prescription Database (NorPD) was linked to the MoBa cohort 
database to characterize exposure to hormonal contraceptives 12 months before, 4 months 
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before, 1 month before conception, and within 12 weeks after conception (for women 
enrolled 2004 or later).  By Norwegian law, as of January 1, 2004, all pharmacies must 
provide electronic data for all prescriptions dispensed.  NorPD contains individual-level data 
on all medications prescribed and dispensed through pharmacies to non-institutionalized 
individuals in Norway.  Classification of drugs is based on the Anatomical Therapeutic 
Chemical (ATC) classification system.(59)  The Norwegian Institute of Public Health has 
data quality assurance measures for the data collection that include routine evaluation of 
data completeness and errors.  In Norway, between 2004-2006 and based on data collected 
through the NorPD, an estimated 5.2%, 0.2%, and 0.1% of women during their 1st, 2nd, and 
3rd trimesters of pregnancy, respectively, were dispensed pharmacologic sex hormones.  
During the 1st trimester, 1.5% of women were using sex hormones for contraception and 
2.6% were using sex hormones in association with assisted reproductive therapy.(60)  In the 
three months prior to conception, 11.5% of women used pharmacologic sex hormones.   
2.3 Study inclusionary/exclusionary criteria 
For the purposes of this study, we included all pregnancies conceived after January 
1, 2004, resulting in a singleton live birth and without evidence of having received infertility 
treatment for the index pregnancy.  We also excluded pregnancies to women with a history 
of chronic hypertension and, for assessing the relationship between hormonal contraceptive 
use and offspring overweight or obesity, infants who died in the first year of life.   
2.4 Outcome and exposure assessment 
This study examined the association between hormonal contraceptives and fetal 
growth indicators (weight for gestational age expressed as a continuous measure of 
birthweight z-score and as a categorical measure of small versus average or large for 
gestational age) and on body mass index at 36 months of age (expressed as both an age 
and sex-adjusted continuous measure of weight for age and sex z-score and as a 
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categorical measure of underweight or normal weight versus overweight or obese).  
Because childhood obesity status may be influenced by gestational length at birth,(61) we 
also examined the association between hormonal contraceptive use and preterm birth, both 
as a categorical measure of preterm birth and as a continuous measure of gestational 





















Exposure assessment  
There were two possible sources of information for hormonal contraceptive use for 
this study -- self-reported use as reflected on the MoBa questionnaire administered at 17 
weeks and the NorPD indicated dispensing of hormonal contraceptives.  Ultimately, we 
chose using the NorPD for assessing exposure to hormonal contraceptives, as there were 
several limitations to using the self-reported data.   
On the MoBa questionnaire administered at about 17 weeks gestation, women report 
contraceptive use in the 4 months and in the 12 months before conception.  Women also 
report whether they were using contraceptives at the time at which they conceived.  In 
reporting oral contraceptive use in 12 months before conception and at conception, women 
report whether they were using the progestin-only “mini-pill” or the combination “pill”.  
Figure 2.1. Study data sources 
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Women had the option of selecting both the combination and progestin-only pill in the year 
prior to pregnancy.  Women did not differentiate between which forms of oral contraceptive 
they used in the 4 months before pregnancy.  Although we could have imputed the type of 
contraceptive used at 4 months by carrying forward the type of oral contraceptive used in 
the 12 months before conception, misclassification in characterization of exposure could 
have occurred in using this approach.  It is possible that some women will have been 
uncomfortable self-reporting oral contraceptive use at the time of pregnancy.  Other 
limitations in using self-reported exposure were that use of some forms of hormonal 
contraceptives was not collected.  Furthermore, there is a potential that some women may 
not have accurately remembered the type of contraceptive used.  Finally, self-reported data 
would have precluded assessing for potential associations by hormonal contraceptive 
formulation, including evaluation by progestin type.  
Linkage to NorPD provided the date(s) and specific formulation of oral 
contraceptive(s) prescribed and dispensed to women in MoBa, but is limited to women 
enrolled in MoBa after 2003.  Of the 107,378 pregnancies enrolled in MoBa, there were 
32,949 pregnancies enrolled between study inception through 2003.(57)  To estimate use in 
the 12 months preceding conception, we restricted the study population to pregnancies 
conceived at least 12 months after the date the NorPD registry began.  Variables included in 
the linked file are presented below (Table 2.2). 
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Table 2.2. Description of variables in linked file 
Variable Description Valid values 
Prescriber     
Prescriber's serial 
number 
Number is generated from prescriber's ID 
number in health personnel's register  
Serial number - unique for 
every dispensing.   
Prescriber's profession  Physician, dentist, veterinary 
surgeon, nurse, midwife, 
optician, other profession, 
profession lacking 
Prescriber's specialty  General practitioner, children's 
illnesses, internal medicine 
Patient     
Patient's residential 
municipality number 
Patient's place of residence at time of 
dispensing of drug. Municipality number 
contains 4 digits, first two for county, last 
two for municipality.  
0101, 0104, 0211, 0301 etc 
Patient's residential 
municipality name 




Patient's place of residence at time of 




    
Dispensed 
prescriptions 
    
Dispensing number Serial number for individual dispensed 
prescriptions 
Numerical, number of digits 
will vary 
Dispensing date   yyyy-mm-dd 
Number of packs Dispensed number of packs Numerical, with decimals 
Number of DDD Dispensed number of DDD Numerical, with decimals 
Drug     
Drug's description Name, strength and format Alphanumerical 
Size of packet Number of tablets, gram, ml, etc Numerical 
Packaging unit   Dosage format 
Strength of drug   25mg, 1g, 0.5mg/ml, 
2500IU/syringe etc  
ATC code Drug's ATC code 1. - 5  Alphanumerical 
DDD Defined daily dosage (DDD) for ATC code  Numerical, up to 3 decimals 
DDD unit Unit of measurement for DDD g, mg, IU etc 
Dispensing group Prescription category set by Norwegian 
Medicine Agency 
Norwegian Prescription 
Category (A, B, C, F(OTC)) 
Pack's recommended 
retail price (RRP) at 
point of sale 
Pharmacy retail price at point of sale Norwegian kroner 00.00 
Source: National Institute of Public Health, Oslo, Norway 
Date of conception was estimated by subtracting 17 days(62) from the number of 
days of gestational length at birth (to account for the follicular phase prior to conception) and 
then subtracting this value from the date of birth.  We used the last menstrual period (LMP)-
based estimated gestational length unless the LMP-based gestational length was missing or 
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≥2 weeks from the ultrasound-based estimate of gestational length, in which case we used 
the ultrasound based measure.(63)  We then constructed an exposure window for each 
hormonal contraceptive prescription filled using the date that the prescription was filled and 
the number of defined daily doses dispensed (day’s supply).  We characterized exposure 
into discrete categories by last date of use relative to conception; specifically last use 12 - 
>4 months before, 4 - >1 months before, and 1 - > 0 months before, and 0 -12 weeks after.  
These exposure categories roughly correspond to the periods of primordial follicular growth 
(12 months before), secondary and primary follicular growth (4 months before), ovulation (1 
month before), and early embryo development (up to 12 weeks after conception).   
Use of the NorPD to characterize exposure was not without limitations.  In using 
NorPD, we could not know about, or be able to characterize, exposure according to how 
well women adhered to guidelines for prescription use.  Women may have had varying 
levels of exposure, depending on how closely they followed the prescription regime.  
Outcome assessment  
Aim 1 (Birth) - For Aim 1, we evaluated the association between hormonal 
contraceptive use and birth weight for gestational age and length of gestation.  These 
outcomes were characterized as follows: 
Birthweight for gestational age z-score:   
Birthweight and gestational age at birth were recorded on the MBRN.  After 
identifying and excluding observations with biologically implausible values (gestational age 
<22 weeks or > 45 weeks or birthweight <1000 grams for infants born at ≥37 weeks), 
birthweight for gestational age was characterized as both a continuous measure (birthweight 
for gestational age z-score), and categorically as small versus average or large for 
gestational age.  Small for gestational age (SGA) was characterized as having been born at 
< 3rd percentile for weight for gestational age.(64)  Weight for gestational age percentile was 
calculated from a population standard as described by Mikolajczyk et al.(65)   
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Gestational length: 
As described previously, we used the last menstrual period (LMP)-based estimated 
gestational length unless the LMP-based gestational length was missing or ≥2 weeks from 
the ultrasound-based estimate of gestational length, in which case we used the ultrasound 
based measure.(63)  Last menstrual period (LMP) derived due dates (Naegele’s rule) can 
be inaccurate due to varying menstrual cycle lengths, uncertainty of LMP, and non-
menstrual bleeding not associated with menses (from OC use or mid-cycle bleeding).  
Ultrasound-based due dates can also be inaccurate as reference values are based on 
expected fetal size values using LMP.  For fetuses that are either small or large for 
gestational age, ultrasound-based due dates will be biased.(66)  Preterm birth was defined 
as delivery before 37 completed weeks of pregnancy,(67) assessed from the gestational 
length in days.   
Aim 2 (36 months of age) - For Aim 2 we evaluated the association between 
hormonal contraceptive use and BMI z-score at age ~36 months.  BMI was characterized as 
follows: 
BMI as a continuous measure: 
Variables for defining the outcome at 36 months of age included child age (in days at 
36 month questionnaire), child sex, and child height and weight.  First, we calculated age 
and sex adjusted z scores for height, weight and weight for height.  The z-scores were 
generated using the World Health Organization (WHO) Child Growth Standards.(68)  BMI 
was calculated by using the standard definition for BMI, kg/m2.(69)  Next, we identified and 
excluded observations with biologically implausible values.  The WHO Standards include 
recommendations for excluding biologically implausible values based on calculated z-scores 
for height, weight and BMI.  Extreme (i.e. biologically implausible) z-scores for each indicator 
were flagged as follows:   
• Weight-for-age z-score (ZWEI) ZWEI<-6 or ZWEI >5  
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• Length/height-for-age z-score (ZLEN) ZLEN<-6 or ZLEN >6  
• Weight-for-length/height z-score (ZWFL) ZWFL<-5 or ZWFL>5  
• BMI-for-age z-score (ZBMI) ZBMI <-5 or ZBMI >5(68) 
We included children with documented height and weight measurements between 30 
months and 42 months of age.    
Overweight or obese at 36 months: 
We characterized children as overweight or obese using BMI cutpoints for 
overweight or obesity as established by the International Obesity Task Force (IOTF).  The 
IOTF generated standard definitions for defining overweight or obese in children using 
pooled data collected from nationally representative data from cross sectional surveys on 
growth in Brazil, Great Britain, Hong Kong, the Netherlands, Singapore, and the United 
States.(70)  The BMI cutpoints are based on child sex and age and, projected out to 
adulthood, correspond to adult overweight or obese.   
2.5 Data analyses  
This was an epidemiologic study of the association between hormonal contraceptive 
use before and in early pregnancy and offspring anthropometric indicators at birth and at 36 
months of age.  We hypothesized that hormonal contraceptives would have a negative 
inverse association with neonatal anthropometric measures and gestational length (Aim 1) 
and a positive association with offspring BMI, odds of overweight or obese at 36 months of 
age (Aim 2).  
Data preparation 
The MoBa cohort data was linked with the MBRN data at the Norwegian Institute of 
Public Health.  For this study, the Norwegian Mother and Child Cohort Study Scientific 
Committee granted permission to link the MoBa/MBRN data with NorPD for characterization 
of sex hormone exposure.  Once the final data sets were received and linked (by the pseudo 
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personal identifier assigned for the purposes of this study), we inspected the data for 
biologically implausible values for study covariates and set to missing those values deemed 
implausible.   
Exposure-outcome analyses  
Aim 1 (birth) - We used generalized linear models to assess the relationship between 
hormonal contraceptive use and continuously measured birth outcomes.  Specifically, we fit 
a linear model (identity link) to assess the association between exogenous sex hormone 
exposure and birth weight for gestational length z-score and length of gestation.  A binomial 
distribution, logistic model (logit link) was used to estimate the odds for preterm birth as 
compared to full term birth.   
Aim 2 (age 3) - We used generalized linear models to assess the relationship 
between exogenous sex hormones and offspring obesity.  We fit a linear model to assess 
the association between exogenous sex hormone exposure and body mass index z-score at 
age 36 months and a logistic model to estimate the odds for overweight or obese versus 
normal weight. 
Aims 1 and 2 - Covariate-outcome relationships were explored non-parametrically 
first, to determine whether covariates should be characterized continuously, using quadratic 
terms, through use of an indicator variable, or with splines.   
Where data were of sufficient sample size, we assessed for effect modification by 
maternal pre-pregnancy BMI (underweight or normal weight versus overweight or obese) 
and by offspring sex through inclusion of an interaction term in the models.  We used the 
Wald-type p-value (p value < 0.20) as an initial screen to assess for evidence of possible 
effect modification by maternal pre-pregnancy BMI or offspring sex.(71)  If there was 
evidence of possible effect modification, we produced stratum specific estimates and 
examined confidence intervals for evidence of overlap.  Significant overlap suggested 
insufficient evidence for effect modification.  If estimates and confidence intervals were 
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disparate, we reported results separately across maternal BMI and/or offspring sex 
categories.  All models used Generalized Estimation Equations (GEE) to obtain robust 
variance estimators and account for multiple children in the study from the same family.  All 
analyses were conducted using SAS 9.3 (SAS Inc, Cary, NC).   
2.6 Study biases  
Confounding   
The association between hormonal contraceptive use and offspring anthropometric 
indicators is likely confounded by multiple factors that are direct or indirect antecedents of 
both the exposure and outcome.  Women who conceive while taking an oral contraception 
are unique in that they may either have poor adherence to taking the oral contraceptive 
and/or they are highly fecund.  With perfect use, the ‘failure’ rate for oral contraceptives is 
<1%.(54)  Fecundity, among women not currently using a hormonal contraceptive, is 
associated with maternal age, prior oral contraceptive use, irregular or long menstrual 
cycles,(72, 73) heavy smoking,(72, 74) heavy alcohol use, pre-pregnancy BMI,(72) and 
some health conditions (polycystic ovarian syndrome, endometriosis,  autoimmune 
disease,(75) and history of cancer treatment).(76)   
Studies on hormonal contraceptive adherence cite parity,(77) unawareness of the 
potential benefits of oral contraception outside of prevention of pregnancy,(78, 79) 
experiencing side effects,(78, 80) and ability to access prescriptions(77) as factors 
contributing to prescription adherence.   
To estimate the association between hormonal contraceptive use and offspring 
anthropometric outcomes, we considered which factors could be antecedents of both 
hormonal contraceptive use and offspring growth.  For early pregnancy use, we further 
considered factors related to hormonal contraceptive adherence.  We used directed acyclic 
graphs (DAGs) to identify the minimally sufficient sets for inclusion of possible study 
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confounders.(81)  Figure 2.2 illustrates a DAG representing the possible relationship 











Figure 2.2. DAG for early pregnancy use of hormonal contraceptives and 
overweight or obesity 
In this DAG, there were several minimally sufficient sets that could have been used 
to minimize the potential for confounding as introduced by these maternal characteristics.   
These included any of the following: 
1. Adherence, Fecundity, Maternal age, Parity, Pre-pregnancy BMI, Maternal smoking 
2. Adherence, Fecundity, Hormonal contraceptive use before conception 
3. Maternal alcohol use, Fecundity, Maternal Age, Maternal education, Hormonal 
contraceptive use before conception, Pre-pregnancy BMI 
 
4. Fecundity, Maternal age, Maternal education, Hormonal contraceptive use before 
conception, Pre-pregnancy BMI, Maternal smoking 
 
5. Maternal education, Parity, Pre-pregnancy BMI, Maternal smoking 
To identify which minimally sufficient set to use, we considered which of the 
















HC use after 
conception 
HC use before 
conception 
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association with the exposure and outcome.  MoBa does not include a measure of 
adherence -- this is an unmeasured variable in this DAG.  Time to conceive could have 
served as a proxy for fecundity.  However, all women who conceive while taking an oral 
contraceptive have had a time to conceive of 0.  Conditioning on time to conceive might 
create convergence issues due to non-positivity or insufficient overlap in distribution of 
covariates.  Given these factors, we selected the set including maternal education, parity, 
pre-pregnancy BMI, and maternal smoking, for our minimally sufficient adjustment set.   
Loss to follow up or out-selection bias   
In assessing the association between hormonal contraceptive use and offspring 
overweight or obesity there was the potential for out-selection bias, resulting from loss to 
follow-up.  If out-selection is associated with covariates that are causal of the exposures of 
interest (or with factors associated with the exposure) and also associated with the outcome, 
there is a potential for introducing collider stratification bias when limiting a sample 
population to the risk set remaining after selection has occurred. 
 Simply adjusting on factors associated with selection may also introduce collider 
stratification bias if there are unmeasured factors associated with selection.  Therefore, we 
used a multiple imputation approach(82) to impute 10 data sets with imputed follow-up data 
for offspring BMI. We modeled the association between hormonal contraceptive exposure 
and offspring overweight or obesity for each of the imputed datasets.  The model results for 
each data set were then synthesized to obtain final estimates for the multiple imputation 
approach.  As an alternative approach to multiple imputation, we also conducted a 
sensitivity analysis using inverse probability weighting to account for loss to follow-up.(83)     
Selection bias due to missing covariate data  
We also explored the degree of missing data present among study covariates.  If 
there had been more than 15% missing on any one of the study covariates or combination 
of study covariates, we would have explored the appropriateness of imputing missing 
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covariate data by first constructing a predictive model for missingness, using covariates and 
outcomes selected for inclusion in the study.  If missing completely at random, missingness 
will not bias estimates but could increase variance.  If missing at random, whereby 
missingness is conditional on one or more covariates under observation, both estimates and 
variance could be biased.  Under the assumption that there were not unobserved study 
variables influencing missingness (in which case multiple imputation would be 
inappropriate), we could have used multiple imputation to impute the missing data.(82) 
Analyses would then be carried out using data with and without imputations to assess the 
sensitivity of the study estimates to imputing missing covariate data.   
2.7 Public health relevance  
This was an epidemiologic study of the influence of pharmacologic sex hormone 
exposure, specifically hormonal contraceptives, on offspring birth outcomes and early 
childhood measures of BMI, overweight or obesity.  Although there is considerable concern 
for the possible risks of exogenous sex hormone exposures conferred through 
environmental sources, these exposures are small and the effects are difficult to assess in 
human populations.  This study explored the risk of pharmaceutical-based sex hormones in 
their own right, but also as a proof of principle for understanding the potential for harm from 
lower dose exposures.   
Extensive efforts have been made to stem the rising tide of obesity, primarily in the 
form of interventions targeted to change individual behavior, specifically increasing physical 
activity and improving dietary behaviors of populations at risk of or already overweight or 
obese.  These efforts have met with limited success and researchers and public health 
advocates recognize that addressing individual diet and exercise behaviors may not fully 
address the growing epidemic of overweight and obesity.  Although it is likely that the 
etiology of overweight and obesity is extremely complex and no single pathway exists in the 
development of overweight or obesity, there are indications that the origins of overweight 
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and obesity may be rooted in insults incurred during fetal development.  This study 
evaluated the association between before and in early pregnancy, exogenous sex hormone 
exposure and altered growth as indicated through offspring anthropometric indicators.  
2.8 Study limitations and other considerations  
This study had a limitation of exploring pharmacologic sex hormone effects before 
and during early pregnancy only.  Although early pregnancy exposure confers the highest 
potential for relative increase in sex hormones, in that this is the period of pregnancy when 
endogenous levels are still relatively low, this study did not assess the risk of relatively low 
dose exposures aggregated over time throughout pregnancy, such as those experienced 
through environmental sources.  It also did not assess the effects of exposure on later onset 
(after age 3) overweight or obesity.  A proposed mechanism underlying this study, described 
previously, suggests that early, preimplantation exposure, may lead to downstream effects 
on fetal development, gestational length, and offspring growth.  However there may be other 
mechanisms, possibly outside this window of exposure that could lead to long-term effects 
on fetal and postnatal growth.  An absence of an association between pharmacologic 
sources of sex hormones and offspring growth indicators at one point in time does not 
preclude the possibility that exogenous sex hormone exposures could confer risk for altered 
growth trajectory of the developing fetus, neonate, or child.   
Although use of prescription registry data offers considerable detail in the timing and 
formulation of the agents prescribed, there is considerable opportunity for misclassification 
of use.  The extent to which women adhered to the guidelines for taking the prescription is 
unknown.  The likelihood for misclassification, likely over-reporting of use, may increase as 
the date of conception approaches given the likelihood that many women will have 
discontinued taking hormonal contraceptives to conceive.  We minimized the potential for 
misclassification of exposure in early pregnancy by indicating early pregnancy use only 
when women also reported the pregnancy was unplanned.    
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CHAPTER 3: HORMONAL CONTRACEPTIVE USE IN RELATION TO PRETERM 
BIRTH AND SMALL FOR GESTATIONAL AGE 
 
3.1 Introduction  
Outcomes at birth, including preterm birth and small for gestational age at birth, can 
serve as markers of impaired or altered fetal growth and development.  The cascade of 
events leading to parturition are not well understood but are believed to involve signaling 
from both the mother and the fetus.(84)  Being small for gestational age, particularly for 
infants born at the extreme lower end of the distribution, can indicate impaired growth during 
fetal development.(85)  Exposure to exogenous sources of hormonally active agents, 
especially during developmentally sensitive periods, may contribute to altered growth and 
development.    
Animal models provide evidence that developmentally sensitive periods begin even 
before conception.(9-13)  The metabolic activity of preimplantation embryos can be changed 
as a consequence of alterations in their environment.(23, 24)  Even subtle environmental 
alterations may lead to altered growth and development of the embryo, early parturition and 
preterm delivery.(25)  
Much of the literature concerning exposure to hormonally active agents has been 
centered on exposure to environmental compounds that may have endocrine effects.  
However there are pharmacologic sources of hormonally active agents too, the most 
obvious being hormonal contraceptives.   
Hormonal contraceptives contain, most commonly, a synthetic estrogen and 
progestin component.  Some forms of hormonal contraceptives contain a progestin
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component only.  Possible adverse effects in pregnancy, resulting from use of hormonal 
contraceptives have been studied.  The results of these studies have been largely 
inconclusive, with no consistent pattern emerging for effects of hormonal contraceptive use 
on pregnancy outcomes.(43-48)  Many of these studies have focused on low birth weight, an 
imperfect measure of fetal growth and development.(86) Hormonal contraceptives contain, 
most commonly, a synthetic estrogen and progestin component.  Some forms of hormonal 
contraceptives contain a progestin component only.  The potential for exposure to these 
exogenous hormones to adversely affect pregnancy has been studied, but no consistent 
patterns of association have emerged.(43-48)  Many of these studies have focused on low 
birth weight, which does not appropriately represent fetal growth and development across all 
gestational ages, and did not account for different  hormones comprising the 
contraceptives.(86) 
To our knowledge, there are no studies of the association between hormonal 
contraceptive use and birth outcomes whereby exposure to hormonal contraceptives was 
evaluated according to progestin type.  We are also not aware of any studies evaluating 
birth outcomes for users of the progestin-only oral contraceptive.  Given the differences in 
metabolic effects from hormonal contraceptive formulations with varying progestin 
components,(18-20, 87)  and the relationship between maternal metabolic factors and 
offspring birth outcomes, evaluating the association between hormonal contraceptive by 
progestin type is warranted. 
We used the Norwegian Mother and Child Cohort Study (MoBa), a prospective, 
population-based cohort study conducted by the Norwegian Institute of Public Health,(57, 
58) to evaluate the association between hormonal contraceptive use before and in early 
pregnancy, and birth outcomes.  The data collected through the MoBa cohort study was 
linked to the Norwegian Prescription Registry data (NorPD), and to the Medical Birth 
Registry of Norway (MBRN) data.  In linking to the prescription registry, the formulation of 
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hormonal contraceptive could be characterized with finer detail than has been described 
previously.   
3.2 Methods  
Primary analyses 
Study population: 
MoBa study participants were recruited from 1999 through 2008.  Women were 
identified for eligibility when scheduling the routine prenatal ultrasound offered free of 
charge to all pregnant women in Norway at 17-20 weeks of gestation. Women were then 
mailed an invitation to participate before the scheduled ultrasound, with informed consent 
and enrollment taking place at the ultrasound examination.  All hospitals with at least 100 
births per year participated in the study recruitment and enrollment.  Approximately 42 
percent of all pregnant women in Norway were invited to participate in the study.  Of these, 
39 percent consented to participate.  At enrollment, participants were asked to provide a 
blood sample and to complete an initial, self-administered questionnaire to provide data on 
demographic characteristics, reproductive health history, disease and medication history, 
lifestyle factors, and socioeconomic status.  Follow-up is ongoing and is conducted through 
self-administered questionnaires at regular intervals and by linkage to national health 
registries. 
All MBRN birth registry data are collected on a standardized birth notification form 
completed by the midwife or physician attending the birth.  Prescription data from NorPD 
contains individual-level data on all medications prescribed and dispensed through 
pharmacies to non-institutionalized individuals in Norway.  By Norwegian law, as of January 
1, 2004, all pharmacies must provide electronic data for all prescriptions dispensed.   
There were 107,308 pregnancies in the MoBa cohort.  For the present analysis, we 
included pregnancies resulting in a singleton live birth and excluded pregnancies with 
documentation of infertility treatment for the index pregnancy, on either the MoBa 17-week 
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questionnaire or the MBRN.  We additionally excluded pregnancies to women who had 
documented pre-pregnancy chronic hypertension (n=527).  As the NorPD registry was not 
initiated until January 1, 2004, we further restricted our study population to pregnancies of 
women enrolled at least 12 months after the date on which the NorPD registry began 
collection of data on prescription fills (n=48,615).  We excluded pregnancies with missing 
covariate data (n=4,191).  The final study population included 44,734 pregnancies to 42,155 




All Norwegian residents are assigned a personal identifier number.  Linkage of the 
MoBa questionnaire, MBRN, and NorPD data files were possible through this identifier.  The 
Figure 3.1. Study population selection 
for Aim 1 
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University of North Carolina at Chapel Hill and the National Institute of Environmental Health 
Sciences Institutional Review Boards and the Norwegian Southeastern Regional Ethics 
Committee reviewed and approved this study.   
Exposure: 
Hormonal contraceptive use in early pregnancy and prior to conception was 
characterized according to the Anatomical Therapeutic Chemical (ATC) Classification 
System.(59)  We characterized exposure by type and route of administration (combination 
oral contraceptive, progestin-only oral contraceptive, vaginal ring, transdermal, injectable, 
implant, and hormonal-based intrauterine device) and by type, route, and progestin 
component.  All hormonal contraceptives with an estrogen component (combination oral 
contraceptives, vaginal ring, and the transdermal contraceptive) contained ethinyl estradiol, 
but there were eight different progestin types used solely or in combination with ethinyl 
estradiol, including desogestrel, drospirenone, levonorgestrel, norelgestromin, 
norethisterone, lynestronol, medroxyprogesterone, and etonogestrel.   
Date of conception was estimated by subtracting 17 days(62) from the total number 
of days of gestation (to account for the follicular phase prior to conception) and then 
subtracting this value from the date of birth.  We used the last menstrual period (LMP)-
based estimated gestational length unless the LMP-based gestational length was missing or 
≥2 weeks different from the ultrasound-based estimate of gestational length, in which case 
we used the ultrasound based measure.(63)  We then constructed an exposure window for 
each hormonal contraceptive prescription filled using the date that the prescription was filled 
and the number of defined daily doses dispensed (day’s supply).  We characterized 
exposure into discrete categories relative to conception; specifically last use 12 - >4 months 
before, 4 - >1 months before, and 1 - > 0 months before, and 0 -12 weeks after.  Women 
using hormonal contraceptives in early pregnancy were also using hormonal contraceptives 
before pregnancy.  In our analyses, we evaluated last date of use as compared to no 
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hormonal contraceptive use within any of the exposure periods assessed.  For example, 
women whose last date of use was 1, 4, or 12 months before conception were not included 
in the analysis evaluating use within 12 weeks after conception.   
Most oral contraceptives were dispensed in 3-month supply (82%) or 6-month supply 
(15%).  For pregnancies with more than one type of hormonal contraceptive prescribed, we 
assigned exposure type according to the type of contraceptive used closest to the estimated 
date of conception.  Because many women may stop taking their hormonal contraceptive in 
order to achieve conception, we characterized women as exposed in early pregnancy only if 
they reported on the 17-week questionnaire that the pregnancy was unplanned and they 
had ≥ 1 day(s) supply of hormonal contraceptive at or after the day of conception as defined 
above.  
Outcome: 
Preterm birth was defined as delivery before 37 completed weeks of pregnancy,(67) 
assessed from the gestational length in days.  Small for gestational age (SGA) was 
characterized as having been born at <3rd percentile for weight for gestational age.(64)  
Weight for gestational age percentile was calculated from a population standard as 
described by Mikolajczyk et al.(65)  Birthweight z-score was calculated by subtracting the 
observed birthweight from the expected birthweight based on the population standard 
distribution and then dividing this value by the standard deviation for each gestational age.   
Covariates: 
Covariate selection was informed through construction of a directed acyclic 
graph(81) and included adjustment for factors demonstrated to be causal ancestors of both 
contraceptive use and adverse pregnancy outcomes, including preterm delivery and fetal 
growth restriction.  These factors included maternal age (14-19, 20-29, 30-39, 40-49 
years),(72, 73) maternal pre-pregnancy BMI (kg/m2)(<18.5, 18.5-24.9, ≥25.0),(65, 72, 88) 
parity (0, 1, ≥2),(77) maternal smoking (none, former smoker, current smoker),(72, 74) and 
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maternal education (>4 years of university or technical, 4 year university or technical degree, 
3 years of college preparatory high school, 3 years of technical high school, 1-2 years of 
high school, <9 years of secondary school, other).(78, 79)  
Analysis: 
Our primary analyses were concerned with assessing the association between 
hormonal contraceptive use, by type (combination versus progestin-only) and route (oral, 
vaginal, transdermal, and injectable), and preterm birth or SGA within the discrete 
categories of within 12 months, 4 months, and 1 month before conception and within 12 
weeks after conception.  For each exposure period, any contraceptive with < 10 exposed 
cases were combined into a single “other” exposure category.  We used generalized linear 
models with a logit link, and generalized estimation equations (GEE) with an independent 
correlation matrix(89) to estimate associations between exposures and outcomes using 
robust standard errors, accounting for lack of independence between siblings.  
We conducted tests of homogeneity to evaluate whether different progestins in the 
contraceptive formulation were differently associated with preterm birth or SGA.  We used 
generalized linear models to obtain the log likelihood for three, nested models; first modeling 
any hormonal contraceptive use in each of the exposure periods as compared to no use at 
any of the exposure periods, second, hormonal contraceptive use by type and route as 
compared to no use, and third, contraceptive use by type, route and progestin formulation 
as compared to no use.  We conducted likelihood ratio tests to assess whether the model fit 
improved from characterizing exposure with increasing detail.  All analyses were conducted 
using SAS v9.3 (SAS Inc., Cary, North Carolina).   
Sensitivity analyses 
Examination of the covariate distribution among pregnancies with hormonal 
contraceptive use in early pregnancy, as compared to non-users, indicated that women with 
hormonal contraceptive use were generally older and more parous than non-users 
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(Appendix, Supplementary Table S3.1).  There were also differences in the characteristics 
of women using different types of hormonal contraceptives.  For example, while 71% of 
combination oral contraceptive users were nulliparous, just 17.2% of progestin-only oral 
contraceptive users were nulliparous.  These differences suggest that prescribing patterns 
may differ based on individual factors, thus raising the concern for confounding by 
indication.  We explored the robustness of our results through sensitivity analyses designed 
to mitigate the potential for confounding by indication.   
First, because combination oral contraceptive users were much likely to be 
nulliparous than progestin-only oral contraceptive users, we restricted our analysis to 
nulliparous pregnancies only.  This approach was intended to reduce the potential for 
confounding based on differences in prescribing patterns for women who were parous.  
Next, we compared the association comparing combination oral contraceptive use to vaginal 
ring use (Appendix, Supplementary Table S3.1), because these two groups were socio-
demographically most similar.  Finally, we conducted a propensity score analysis to reduce 
residual confounding associated with use of combination oral contraceptives as compared to 
no use of a hormonal contraceptive.    
To construct the propensity scores, we evaluated several models to estimate the 
predicted probability of obtaining a combination oral contraceptive prescription (propensity 
for treatment scores).  We included in the models those factors believed to be associated 
with both use of the combination oral contraceptive and preterm birth (parity, maternal pre-
pregnancy body mass index, maternal age, maternal education, maternal smoking), but that 
preceded the use of a combination oral contraceptive.  We compared the distribution of 
propensity scores among those prescribed a combination hormonal contraceptive to those 
not prescribed any hormonal contraceptive, to evaluate evidence of common support, and 
trimmed any observation for which there was no corresponding propensity score.  We then 
ranked the scores into deciles and assigned each observation a corresponding rank.  We 
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used GEE models to assess the relationship of combination oral contraceptive use with 
preterm birth, with inclusion of an indicator term for rank, and obtained a pooled estimate of 
the association across strata.  In addition to the term for rank, these models included all of 
the potential confounders from the primary analyses models.(90-92)  In evaluating the 
covariate balance within propensity score rank for exposure within 12 months, the 
distribution of study covariates was similar within rank (Appendix, Supplementary Table 
S3.2). 
3.3 Results 
As noted above, there were 44,734 pregnancies that met study inclusionary criteria.  
Of these, nearly all were to women between the ages of 20-39 (97%), approximately half 
were first pregnancies (47.1%), and the majority had at least some college education 
(81.4%).  Roughly a third (30.7%) of the pregnancies were in women who were overweight 
or obese (Table 3.1).   
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Table 3.1. Study population characteristics among women participating in the 
Norwegian Mother Child Prospective Cohort Study (2004-2008) 
 Study population* 
  n=44,734 
Characteristic  % 





Maternal BMI (kg/m2)  
<18.5  3.2 
18.5-24.9 66.0 
25.0-29.9 21.7 






4 or more 0.9 
Maternal education  
More than 4 years of university or technical 27.2 
4 year university degree, regional technical 40.8 
3 years high school, junior college 13.4 
Technical high school 11.2 
1-2 years high school 3.9 
9-year secondary 2.2 
Other 1.4 
Maternal smoking (at 17 weeks)  
None 79.3 
Quit 14.5 
*Represents unique pregnancies conceived without infertility treatments, resulting in a singleton live birth, with a 
date of birth ≥12 months after NorPD registry began (January 1, 2004) 
 
There were 1,969 (4.4%) births before 37 completed weeks of gestation and 1,167 
(2.6%) infants born SGA in the study sample.  After characterizing hormonal contraceptive 
use into discrete exposure windows from which estimates could be obtained for modeling 
the association between use at a given time, there were 7,470 exposed pregnancies within 
12 months before, 5,740 exposed pregnancies within 4 months before, 6,465 exposed 
pregnancies within 1 month before, and 1,638 exposed pregnancies within 12 weeks after 
conception.   
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In evaluating hormonal contraceptive use by type and route of administration, we 
observed a positive association between use of a combination oral contraceptive, as 
compared to no use of a hormonal contraceptive, and preterm birth across all exposure 
periods, with the magnitude of the association remaining relatively consistent regardless of 





Table 3.2. Hormonal contraceptive use and gestational length at birth by period of last use, progestin type, and 
route of administration in the Norwegian Mother Child Prospective Cohort Study (2004-2008) 





OR (95% CI) aOR* (95% CI)  β (95% CI) 
unadjusted 
β (95% CI) 
adjusted* 
None 23,421 964 referent referent  referent referent 
Within 12 weeks after 
conception  
       
Combination OC 1,062 71 1.67 (1.30, 2.14) 1.32 (1.01, 1.73)  -1.19 (-2.08, -0.29) -0.73 (-1.63, 0.18) 
Progestin-only OC 359 18 1.23 (0.76, 1.98) 1.26 (0.78, 2.04)  -0.52 (-1.75, 0.71) -0.47 (-1.70, 0.76) 
Other**  217 5 0.55 (0.23, 1.34) 0.49 (0.20, 1.21)  1.28 (-0.29, 2.85) 1.48 (-0.11, 3.06) 
Within 1 month before 
conception  
       
Combination OC 4,660 225 1.18 (1.02, 1.37)  1.13 (0.97, 1.31)  0.11 (-0.30, 0.51) -0.09 (-0.50, 0.33) 
Progestin-only OC 1,204 30 0.60 (0.41, 0.86) 0.67 (0.46, 0.97)  0.87 (0.26, 1.48) 0.66 (0.05, 1.27) 
Vaginal ring 356 13 0.88 (0.51, 1.54) 0.86 (0.49, 1.51)  0.18 (-1.06, 1.43) -0.10 (-1.35, 1.16) 
Other ** 245 7 0.69 (0.32, 1.46) 0.66 (0.31, 1.42)  0.16 (-1.16, 1.48) 0.05 (-1.27, 1.36) 
Within 4 months before 
conception 
       
Combination OC 3,833 213 1.37 (1.18, 1.60) 1.31 (1.11, 1.53)  -0.49 (-0.93, -0.04) -0.73 (-1.19, -0.26) 
Progestin-only OC 1,284 53 1.00 (0.76, 1.33) 1.15 (0.87, 1.53)  0.39 (-0.27, 1.05) 0.18 (-0.48, 0.85) 
Vaginal ring 352 12 0.82 (0.46, 1.47) 0.80 (0.45, 1.43)  0.32 (-0.89, 1.52) 0.04 (-1.16, 1.25) 
Other ** 271 9 0.80 (0.41, 1.56) 0.76 (0.39, 1.49)  0.39 (-0.83, 1.61) 0.30 (-0.93, 1.52) 
Within 12 months before 
conception  
       
Combination OC 4,633 241 1.28 (1.11, 1.48) 1.21 (1.04, 1.41)  -0.10 (-0.51, 0.31) -0.31 (-0.74, 0.11) 
Progestin-only OC 1,795 71 0.96 (0.75, 1.23) 1.10 (0.85, 1.40)  -0.38 (-0.96, 0.19) -0.56 (-1.14, 0.001) 
Vaginal ring 424 12 0.68 (0.38, 1.21) 0.68 (0.38, 1.20)  0.83 (-0.32, 1.98) 0.54 (-0.63, 1.70) 
Transdermal 295 10 0.82 (0.43, 1.54) 0.78 (0.41, 1.48)  1.12 (-0.11, 2.34) 1.03 (-0.19, 2.25) 
Injectable 180 14 1.96 (1.13, 3.40) 1.83 (1.06, 3.18)  -1.58 (-3.49, 0.33) -1.72 (-3.95, 0.50) 
Other ** 143 1 0.16 (0.02, 1.17) 0.18 (0.02, 1.27)  2.47 (0.99, 3.96) 2.56 (1.07, 4.05) 
*Adjusted for parity, maternal education, maternal pre-pregnancy BMI, maternal smoking, and maternal age at birth 
**Hormonal contraceptive types with <10 exposed cases collapsed into a single "other" category
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For the progestin-only oral contraceptive, we observed an inverse association with 
preterm birth for use within 1 month of conception (aOR: 0.67, 95% CI: 0.46, 0.97) and a 
positive, but imprecise association at each of the other exposure periods.  No other 
associations with preterm birth were observed except for use of an injectable contraceptive 
at 12 months before conception.  Use of an injectable contraceptive, at 12 months before 
conception, was positively associated with preterm birth (aOR: 1.83, 95% CI: 1.06, 3.18).  
Data were too sparse to evaluate the association between the injectable and preterm birth 
for any of the exposure periods.  The association between use of a hormonal contraceptive 
and gestational length, in days, was generally consistent with the estimates obtained from 
modeling the association with preterm birth.  For the combination oral contraceptive, the 
predicted reduction in mean days of gestational length, given exposure within 12 weeks 
after conception was -0.73 days (95% CI: -1.63, 0.18) (Table 3.2).   
Likelihood ratio tests indicated improved model fit (p<0.05) when characterizing 
exposure by type, route, and progestin component for exposure periods of within 4 months 
and 1 month before conception, and within 12 weeks after conception.  For example, for 
exposure with 12 weeks of conception the magnitude of the association for use of a 
combination oral contraceptive with norethisterone was much stronger (aOR: 3.33, 95% CI: 
1.69, 6.57) than the magnitude of the association for the combination oral contraceptive 
containing drospirenone (aOR: 1.17, 95% CI: 0.76, 1.80).  Similarly, by evaluating the 
progestin-only oral contraceptive by progestin type, we observed a strong association 
between use of the norethisterone progestin-only oral contraceptive within 12 weeks after 
conception and preterm birth (aOR: 2.02, 95% CI: 1.03, 1.79).  Data were too sparse to 
evaluate other forms of the progestin-only oral contraceptive by progestin type for exposure 
within 12 weeks after conception.  Norethisterone in the combination oral contraceptive was 
consistently positively associated with preterm birth for each exposure period.   
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The magnitude of the association with norethisterone was strongest for early 
pregnancy exposure; however evaluation of a trend across all exposure periods did not 
provide support for any dose response.  Norethisterone in the progestin-only oral 
contraceptive was not associated with preterm birth at any of the other exposure periods 
(Table 3.3).  
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Table 3.3. Hormonal contraceptive use and preterm birth by period of last use, 
progestin type, and route of administration in the Norwegian Mother Child 
Prospective Cohort Study (2004-2008) 
Exposure Exposed (n) Preterm (n) OR (95% CI) aOR* (95% CI) 
None 23,421 964 referent referent 
 
Within 12 weeks after conception  
Combination OC     
drospirenone and EE 368 22 1.48 (0.96, 2.29) 1.17 (0.76, 1.80) 
levonorgestrel and EE 545 34 1.55 (1.09, 2.21) 1.20 (0.83, 1.74) 
norethisterone and EE 75 11 4.00 (2.10, 7.62) 3.33 (1.69, 6.57) 
Progestin-only OC         
norethisterone 146 11 1.90 (1.02, 3.52) 2.02 (1.09, 3.75) 
Other** 504 16 0.76 (0.46, 1.26) 0.69 (0.41, 1.15) 
     
Within 1 month before conception  
Combination OC         
desogestrel and EE 295 25 2.16 (1.42, 3.27) 2.09 (1.38, 3.16) 
drospirenone and EE 1,472 61 1.01 (0.77, 1.31) 0.95 (0.73, 1.24) 
levonorgestrel and EE 2,521 120 1.16 (0.96, 1.41) 1.11 (0.91, 1.36) 
norethisterone and EE 372 19 1.25 (0.79, 2.00) 1.21 (0.76, 1.93) 
Progestin-only OC         
desogestrel 690 17 0.59 (0.36, 0.96) 0.65 (0.40, 1.06) 
norethisterone 483 13 0.64 (0.37, 1.12) 0.74 (0.43, 1.29) 
Vaginal ring         
etonogestrel and EE 356 13 0.88 (0.51, 1.54) 0.86 (0.49, 1.51) 
Other** 276 7 0.61 (0.29, 1.29) 0.60 (0.28, 1.28) 
     
Within 4 months before conception 
Combination OC         
desogestrel and EE 197 11 1.38 (0.75, 2.54) 1.27 (0.69, 2.35) 
drospirenone and EE 1,227 56 1.11 (0.85, 1.47) 1.07 (0.80, 1.41) 
levonorgestrel and EE 2,107 125 1.47 (1.21, 1.78) 1.40 (1.15, 1.70) 
norethisterone and EE 302 21 1.74 (1.11, 2.72) 1.67 (1.06, 2.62) 
Progestin-only OC         
desogestrel 817 34 1.01 (0.71, 1.43) 1.15 (0.81, 1.63) 
norethisterone 417 16 0.93 (0.56, 1.54) 1.09 (0.66, 1.80) 
Vaginal ring         
etonogestrel and EE 352 12 0.82 (0.46, 1.47) 0.80 (0.45, 1.43) 
Other** 321 12 0.90 (0.51, 1.62) 0.89 (0.50, 1.60) 
     
Within 12 months before conception  
Combination OC         
desogestrel and EE 215 17 2.00 (1.21, 3.30) 1.86 (1.13, 3.09) 
drospirenone and EE 1,475 79 1.32 (1.04, 1.67) 1.25 (0.99, 1.60) 
levonorgestrel and EE 2,605 122 1.14 (0.94, 1.39) 1.09 (0.89, 1.33) 
norethisterone and EE 338 23 1.70 (1.11, 2.61) 1.61 (1.05, 2.49) 
Progestin-only OC         
desogestrel 1,031 42 0.99 (0.72, 1.36) 1.13 (0.82, 1.55) 
norethisterone 640 22 0.83 (0.54, 1.28) 0.95 (0.62, 1.47) 
Vaginal ring         
etonogestrel and EE 424 12 0.68 (0.38, 1.21) 0.67 (0.38, 1.20) 
Transdermal patch     
Norelgestromin and EE 295 10 0.82 (0.43, 1.54) 0.78 (0.41, 1.48) 
Injectable         
medroxyprogesterone 180 14 1.96 (1.13, 3.40) 1.83 (1.06, 3.18) 
Other** 267 8 0.72 (0.36, 1.46) 0.79 (0.39, 1.60) 
*Adjusted for parity, maternal education, maternal pre-pregnancy BMI, maternal smoking, and maternal age at birth 
**Hormonal contraceptive types with <10 exposed cases collapsed into a single "other" category 
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Levonorgestrel, the most commonly prescribed progestin type in combination oral 
contraceptives, was weakly associated with preterm birth for exposure within 12 weeks of 
conception (aOR: 1.20, 95% CI: 0.83, 1.80) and moderately associated with preterm birth for 
exposure within 4 months of conception (aOR: 1.40, 95% CI: 1.15, 1.70).  No association was 
observed for levonorgestrel at 12 months before or 1 month before conception (Table 3.3).   
With the exception of use within 12 months of conception, the combination oral 
contraceptive containing drospirenone progestin was generally not associated with preterm 
birth.  Etonogestrel, in the vaginal ring, and norelgestromin, in the transdermal hormonal 
contraceptive, were also not associated with preterm birth at any of the exposure periods (Table 
3.3).   
Medroxyprogesterone was the only progestin used as an injectable among women in 
this sample and, as described above, was moderately associated with preterm birth for 
exposure within 12 months before conception (Table 3.3).   
We observed no association between use of a hormonal contraceptive, for any of the 
exposure periods, and increased odds of SGA or birthweight z-score.  We observed an inverse 
relation with use of a progestin-only oral contraceptive and SGA for exposure within 4 months 
and 1 month of conception.  Sparse data precluded evaluation of the association between early 
pregnancy use of a progestin-only oral contraceptive and SGA (Appendix, Supplementary Table 
S3.3), as well as individual progestin types for the progestin-only oral contraceptive (Appendix, 
Supplementary Table S3.4).   
In sensitivity analysis, estimates observed in our primary analyses were robust to 
restriction of the study sample to nulliparous pregnancies (Appendix, Supplementary Table 
S3.5).  When restricting the comparator population to vaginal ring users within the same 
exposure period, the magnitude of the association observed for combination oral contraceptive 
users and preterm birth strengthened (aOR at 12 months: 1.78, 95% CI: 0.99, 3.21), however 
wider confidence intervals reflect the degree of uncertainty in estimates obtained in the 
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markedly reduced sample size for these analyses (Appendix, Supplementary Table S3.6). The 
association between the combination oral contraceptive and preterm birth, at all exposure 
periods, was similarly robust to approaches employing use of propensity scores (Appendix, 
Supplementary Table S3.7).   
3.4 Discussion 
In the present study we observed that some formulations of hormonal contraceptive use, 
especially combination oral contraceptives, were associated with a higher probability of preterm 
birth and shorter gestational length.  The positive association for the combination oral 
contraceptive was observed across all exposure periods and was robust to sensitivity analyses.  
There was little evidence of a dose response effect, or change in estimate as the proximity of 
the exposure period approached or included time after conception.  The consistency in the 
magnitude of the association, irrespective of exposure period, could be evidence of an 
association with long-term (>12 months) use, in which case proximity of exposure to conception 
may be less important.  A study evaluating duration of use of oral contraceptives and offspring 
birthweight identified that long-term use (> 2 years), as compared to short-term use (<12 
months), was associated with increased birthweight.(48)  This consistency across exposure 
periods could also be evidence of residual confounding.   
Although use of a pharmacy-based registry offers the benefit of studying specific 
formulations of contraceptives dispensed at specific times, the registry data is only a proxy for 
actual use of the contraceptives.  Classification of exposure in early pregnancy was limited to 
pregnancies reported to be unplanned to increase the potential that prescribed contraceptives 
were actually being used, but for exposure in other periods before pregnancy, fewer women 
may have still been taking a hormonal contraceptive than estimated.  The consistent attenuation 
in adjusted associations at the 1-month before conception exposure interval, as compared to 
other exposure periods, may reflect the higher potential for misclassification in this exposure 
period.   
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The association between the combination oral contraceptive and preterm birth was 
robust to several sensitivity analyses evaluating potential for uncontrolled confounding in our 
primary analyses.  Although our results were robust to these different approaches, confounding 
by indication is still possible.  There may be factors we did not include in our models -- factors 
not in our dataset, which lead to differential use of hormonal contraceptives and are associated 
with pregnancy outcomes.  For example, prescribing practices of hormonal contraceptives are 
often dictated by an individual woman’s estrogen, progesterone, androgen sensitivities or 
excess, as evidenced by her menstrual cycle characteristics(87) and these factors could 
confound the association between hormonal contraceptives and preterm birth.  Still, the 
propensity score models provide additional support for the associations observed in our primary 
analyses assuming we have accurately predicted prescribing of a combination oral 
contraceptive.   
Characterizing exposure in finer detail by type, route of administration, and progestin 
formulation identified differences in association by progestin type.  These differences are not 
surprising.  The effects of hormonal contraceptives vary and are largely driven by the progestin 
component and the pharmacodynamics of progestin and ethinyl estradiol taken in combination.    
For example, some progestin formulations, such as levonorgestrel, are androgenic, while 
others, such as drospirenone, have no affinity for androgen receptor binding.(87, 93)  The 
capacity of the progestin to bind to androgen, mineralocorticoid, and glucocorticoid receptors is 
thought to be a major determinant of the differential actions of progestins in eliciting adverse 
effects in women,(94) including elevating very low-density lipoprotein cholesterol levels and total 
triglycerides.(18-20, 87)  Hormonal contraceptives also increase blood glucose levels, insulin 
levels, plasma cortisol levels,(20) and induce a state of insulin resistance.(18, 19, 87)  Some of 
the metabolic changes elicited by hormonal contraceptives are similar to the metabolic changes 
that occur in women who are overweight or obese.(21, 22)  In the animal models, maternal 
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obesity has led to an increase in the number of apoptotic follicles in the ovaries, smaller and 
fewer oocytes, and smaller pups at birth.(27, 28)   
Medroxyprogesterone, in the injectable hormonal contraceptive, was associated with 
preterm birth.  Medroxyprogesterone readily binds to the glucocorticoid receptor.(93, 94)  
Excess glucocorticoid hormone, through endogenous or exogenous sources, is associated with 
low birthweight and is hypothesized to contribute to fetal programming for adult metabolic 
disease.(95)   
We compared associations over exposure periods, assessing for consistency of effect or 
evidence of possible dose effects according to proximity of exposure to conception.  The 
association with combination oral contraceptives containing norethisterone was consistent 
across exposure periods.  Norethisterone, unlike levonorgestrel, desogestrel, and drospirenone, 
has estrogenic activity.  Norethisterone, in the progestin-only oral contraceptive, was associated 
only with preterm birth for exposure in early pregnancy.  It may be that the association with 
norethisterone, for use before pregnancy, is observed only in the presence of ethinyl estradiol.  
The estrogenic component of a hormonal contraceptive increases the effect of the progestin 
component by increasing the number of intracellular progesterone receptors, thus increasing the 
opportunity for progesterone binding and subsequent signaling.(7, 17) 
In some instances, data were too sparse to evaluate all formulations at every exposure 
period, limiting our capacity to explore differences across time for some agents.  One 
explanation for differing results across different exposure periods is the inherent differences 
among women at the different exposure periods.  Women who did not conceive for up to 12 
months after stopping their hormonal contraceptive could be less fecund or have a different 
metabolic milieu than women who conceived within 4 months or 1 month of stopping their 
contraceptive.  These underlying differences could result in different effects of exogenous 
sources of estrogen and progesterone between women.  
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Exposure to exogenous hormonally active agents may exert adverse agent-specific 
effects on growth and development. Because pharmacologic sources of exposure are prevalent 
due to the frequent use of hormonal contraceptives among women of childbearing age, 
additional research is warranted.  We found that the particular progestin component is important 
when assessing the potential for adverse effects in pregnancy for former users of hormonal 
contraceptives.  The present study provides support for the potential for environmental sources 
of hormonally active agents to exert developmental effects.        
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CHAPTER 4: MATERNAL HORMONAL CONTRACEPTIVE USE AND OFFSPRING 
OVERWEIGHT OR OBESITY 
 
4.1 Introduction  
Worldwide, the prevalence of childhood overweight and obesity increased from 4.2 
percent in 1990 to 6.7 percent in 2010. (1-3)  Children who are overweight or obese are 
more likely to be overweight in adulthood and to suffer from obesity-related morbidity and 
mortality.(5, 6)  The obesity epidemic has been primarily attributed to changes in dietary and 
physical activity behaviors in developed countries, but there is evidence that exposure to 
estrogen-mimicking compounds during developmentally sensitive periods may contribute.   
Although estrogenic agents can signal via non-receptor driven pathways, their 
primary actions are mediated by binding with nuclear receptors that then promote or repress 
transcription of specific genes.(96)  Several studies performed in vitro suggest that 
estrogenic agents can affect adipogenesis.  For example, the potent synthetic estrogen 
diethylstilbestrol (DES) activates expression of both ER and PPAR-γ receptors, both of 
which are required for adipogenesis(97).  Similarly, 17-β estradiol has resulted in increased 
preadipocyte proliferation, likely though up-regulation of PPAR-γ.(98)  Preadipocyte 
formation can be initiated at any stage of life, but perturbation can occur as early as in the 
blastocyst stage.(96)  More recently, epigenetic effects of obesogens have been described, 
whereby alterations in gene expression are driven by DNA methylation or histone 
modifications.  These epigenetic effects may perturb priming of multipotent stem cells to 
promote preadipocyte formation.(36)   
Experiments in animal models have shown a positive association between in utero 
and neonatal exogenous estrogen exposure and metabolic disruption in the offspring,
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including offspring overweight or obesity.(39, 41)  The experimental studies of exposure to 
hormonally active compounds generally address the risk of low-dose exposure to 
environmental sources of estrogen-mimicking compounds.(36-39)  However, in utero 
exposure to androgens has also been associated with offspring obesity.(99-101)  Hormonal 
contraceptives can be androgenic, depending on the progestin component included.  Some 
studies have suggested that these developmental effects on growth may be sex-dependent, 
with associations primarily demonstrated in male offspring.(40)    
The maternal metabolic milieu is also associated with offspring overweight or 
obesity.(25, 102)  Hormonal contraceptives have, for many women, unintended metabolic 
effects, including elevating levels of very low-density lipoprotein cholesterol levels and total 
triglycerides.(18-20, 87)  Hormonal contraceptives increase blood glucose levels, increase 
insulin levels, increase plasma cortisol levels(20) and induce a state of insulin 
resistance.(18, 19, 87)  Some of the metabolic changes elicited by hormonal contraceptives 
are similar to the metabolic changes that occur in women who are overweight or obese, 
specifically increased total cholesterol(21) and increased insulin resistance.(22)  
Given the existing experimental data suggesting that hormonal compounds directly 
cause changes in follicular,(9-13) embryonic, and fetal development,(23, 24) and that they 
may indirectly cause an obesity-like metabolic milieu,(28) studies of hormonal contraceptive 
exposure and offspring development in humans are needed.  
The potential risks of exogenous sex hormone exposure on offspring overweight or 
obesity are difficult to assess in human populations.  Most cohort studies lack the power to 
evaluate the association between exogenous sex hormone exposures during pregnancy and 
offspring obesity because use of pharmacologic sex hormones in early pregnancy is 
relatively uncommon.  Hormonal contraceptive failure, even with imperfect use, is only about 
3%.(54)  With over 40,000 children followed to age 3, the Norwegian Mother and Child 
Cohort Study (MoBa), a prospective, population-based cohort study conducted by the 
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Norwegian Institute of Public Health,(57, 58) offers an unusual opportunity to assess the 
influence of in utero exposure to exogenous sex hormones, through hormonal contraceptive 
use in early pregnancy, on childhood overweight or obesity.  In the present study, through 
linkage of data collected through the MoBa cohort study, the Norwegian Prescription 
Registry data (NorPD), and the Medical Birth Registry of Norway (MBRN) data, we 
evaluated the association between hormonal contraceptive use and offspring overweight or 
obesity at 36 months of age.  
4.2 Methods 
MoBa study participants were recruited In Norway from 1999 through 2008.  Women 
were identified for eligibility when scheduling the routine prenatal ultrasound offered free of 
charge to all pregnant women in Norway at 17-20 weeks of gestation.  Women were then 
mailed an invitation to participate before the scheduled ultrasound, with informed consent 
and enrollment taking place at the ultrasound examination.  All hospitals with at least 100 
births per year participated in the study recruitment and enrollment.  Approximately 42 
percent of all pregnant women in Norway were invited to participate in the study.  Of these, 
39 percent consented to participate.  At enrollment, participants were asked to provide a 
blood specimen and to complete an initial, self-administered questionnaire to collect data on 
demographic characteristics, reproductive health history, disease and medication history, 
lifestyle factors, and socioeconomic status.  Follow-up is conducted through self-
administered questionnaires at regular intervals and by linkage to national health registries. 
All MBRN birth registry data are collected on a standardized birth notification form 
completed by the midwife or physician attending the birth.  Prescription data from NorPD 
contains individual-level data on all medications prescribed and dispensed through 
pharmacies to non-institutionalized individuals in Norway.  By Norwegian law, as of January 
1, 2004, all pharmacies must provide electronic data for all prescriptions dispensed.   
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There were 107,308 pregnancies in the MoBa cohort.  For the present analysis, we 
included pregnancies resulting in a singleton live birth, with no indication of death in the first 
year of life, and with no documentation, on either the MoBa 17-week questionnaire or the 
MBRN, of having received infertility treatment for the index pregnancy.  We additionally 
excluded pregnancies to women with documentation of having pre-pregnancy chronic 
hypertension (n=527).  As the NorPD registry was not initiated until January 1, 2004, we 
further restricted our study population to pregnancies of women enrolled at least 12 months 
after the date on which the NorPD registry began collection of data on prescription fills 
(n=48,615).  For the primary analyses, we also excluded pregnancies with missing covariate 
data (n=3,966), and for loss to follow-up at age 3 (n=24,997).  The final study population 




All Norwegian residents are assigned a personal identifier number.  Linkage of the 
MoBa questionnaire, MBRN, and NorPD data files were possible through this identifier.  The 
University of North Carolina at Chapel Hill and the National Institute of Environmental Health 
Sciences Institutional Review Board and the Norwegian Southeastern Regional Ethics 
Committee reviewed and approved this study.   
Hormonal contraceptive use, in early pregnancy and before conception, was 
characterized according to the Anatomical Therapeutic Chemical (ATC) Classification 
System.(59)  We characterized exposure by type and route of administration (combination 
Figure 4.1. Study population selection 
for Aim 2  
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oral contraceptive, progestin-only oral contraceptive, vaginal ring, transdermal, injectable, 
implant, and hormonal-based intrauterine device).  Hormonal contraceptives are a 
heterogenic group of agents, with varying effects on maternal metabolic markers.  
Therefore, in addition to characterizing exposure by type, we also characterized exposure 
by progestin formulation.  All hormonal contraceptives with an estrogen component 
(combination oral contraceptives, vaginal ring, and the transdermal contraceptive) contained 
ethinyl estradiol, but there were eight different progestin types used solely or in combination 
with ethinyl estradiol, including desogestrel, drospirenone, levonorgestrel, norelgestromin, 
norethisterone, lynestronol, medroxyprogesterone, and etonogestrel.  Any exposures with 
fewer than 10 exposed cases we combined into a single “other” category (Appendix, 
Supplementary Table S4.1).   
Although our primary interest was to explore the association between exposure in 
early pregnancy and offspring overweight or obesity, we also characterized exposure into 
hormonal contraceptive use occurring within 12 months, 4 months, and 1 month of 
pregnancy.  Exposure periods were characterized into discrete exposure windows, 
according to last date of use relative to conception, e.g. 12 - >4 months before, 4 - >1 
months before, 1 - > 0 months before, and 0-12 weeks after.   
Date of conception was estimated by subtracting 17 days(62) from the number of 
days of gestational length at birth (to account for the follicular phase prior to conception) and 
then subtracting this value from the date of birth.  We used the last menstrual period (LMP)-
based estimated gestational length unless the LMP-based gestational length was missing or 
≥2 weeks from the ultrasound-based estimate of gestational length, in which case we used 
the ultrasound based measure.(63)  We then constructed an exposure window for each 
hormonal contraceptive prescription filled using the date that the prescription was filled and 
the number of defined daily doses dispensed (day’s supply). Most oral contraceptives were 
dispensed in 3 month supply (82%) or a 6 month supply (15%).  For pregnancies with more 
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than one type of hormonal contraceptive prescribed, we assigned exposure type according 
to the type of contraceptive used closest to the estimated date of conception.  Because 
many women may choose to stop taking their hormonal contraceptive in order to achieve 
conception, we characterized women as exposed in early pregnancy only if they reported on 
the 17-week questionnaire that the pregnancy was unplanned and had ≥ 1 day supply of 
hormonal contraceptive at or after the day of conception as defined above.  
Offspring overweight or obesity was defined by first calculating the offspring body 
mass index (kg/m2) at age 3 from questionnaire-reported height and weight measures.  In 
Norway, families are provided a health card for tracking health-related data for their children.  
Directions included on the questionnaire instructed mothers to record the height, weight, and 
date that the measure was obtained (and documented on the health card) at the 3-year well 
child exam.  Offspring were characterized as overweight or obese using the age- and sex-
specific cut points for overweight or obese developed by the International Obesity Taskforce 
(IOTF).(70)   
Covariate selection was informed through construction of a directed acyclic 
graph(81) and included adjustment for factors demonstrated to be causal ancestors of both 
contraceptive use and childhood overweight or obesity.  These factors included maternal 
age (14-19, 20-29, 30-39, 40-49),(72, 73) maternal pre-pregnancy BMI  (kg/m2)(<18.5, 18.5-
24.9, ≥25.0),(72, 88, 103) parity (0, 1, ≥2),(77, 104) maternal smoking (none, quit during 
pregnancy, smoker),(72, 74, 105) and maternal education (>4 years of university or 
technical, 4 year university or technical degree, 3 years of college preparatory high school, 3 
years of technical high school, 1-2 years of high school, <9 years of secondary school, 
other).(78, 79, 106)  
Primary analyses  
Our primary analyses were concerned with assessing the association between early 
pregnancy hormonal contraceptive exposure, as compared to no use of a hormonal 
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contraceptive in early pregnancy or within 12 months of pregnancy, and offspring overweight 
or obesity.  We used generalized linear models with a logit link, and generalized estimation 
equations (GEE) with an independent correlation matrix(89) to estimate robust standard 
errors and account for lack of independence between siblings.  We also used generalized 
linear models with GEE to assess the association between hormonal contraceptive use prior 
to conception (within discrete exposure categories of 12 months, four months, and one 
month, as described above) and offspring overweight or obesity. 
Subgroup analyses  
In subgroup analyses, we explored the association between route of administration 
and type of progestin agent and offspring overweight or obesity.  Evaluation of associations 
was conducted only where there were sufficient numbers (≥10) of exposed pregnancies 
resulting in an outcome of overweight or obese at age 3 (Appendix, Supplementary Table 
S4.1).   
We also explored whether there was evidence of interaction between hormonal 
contraceptive use and offspring sex or maternal pre-pregnancy overweight/obese status 
(Yes/No) using interaction terms.  A priori, we considered a p value <0.20 as evidence of 
potential interaction.(71)  If there was evidence of possible interaction, we generated 
stratum-specific estimates of the association between contraceptive use and offspring 
overweight or obesity and examined confidence intervals for the degree of overlap. All 
analyses were conducted using SAS v9.3 (SAS Inc., Cary, North Carolina).   
Sensitivity analyses 
Examination of the covariate distribution among pregnancies to women with 
hormonal contraceptive use in early pregnancy, as compared to non-users, indicated that 
the characteristics of women with hormonal contraceptive use were somewhat different from 
women without contraceptive use (Appendix, Supplementary Table S4.2).  We explored the 
robustness of our primary results using three different comparator groups, selected to more 
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closely approximate the counterfactual population for exposed pregnancies.  These included 
1) a comparator group consisting of women without hormonal contraceptive use in early 
pregnancy but that were reported to be unplanned, to assess for the potential for bias 
resulting from residual factors associated with having an unplanned pregnancy that are also 
associated with offspring overweight or obesity, 2) a comparator group of women who were 
former users of the same contraceptive (within 12 months, but not within 4 months of 
conception or during early pregnancy, to assess for the potential for confounding by 
indication bias -- bias resulting from factors associated with both the type of hormonal 
contraceptive prescribed and with offspring overweight or obesity), and 3) an analysis 
comparing the two oral contraceptive groups: combination vs progestin-only, to account for 
factors associated with oral contraceptive use and childhood overweight that are not related 
to the particular hormone used.  Assuming that any factors contributing to contraceptive 
failure may be similar for different contraceptive types (and that these factors may also be 
associated with offspring overweight or obesity), comparison of progestin-only oral 
contraceptive users as compared to combination oral contraceptive users assesses the 
potential from bias as result of this unmeasured confounding.   
In our sensitivity analysis of exposure to hormonal contraceptive use before 
pregnancy, we evaluated use of the vaginal ring as compared to the combination oral 
contraceptive.  The distribution of study covariates among women obtaining a prescription 
for the vaginal ring was comparable to the distribution of covariates among women obtaining 
a prescription for a combination oral contraceptive (Appendix, Supplementary Table S4.2). 
This approach offered the opportunity to assess the association between vaginal ring users 
and overweight or obesity while minimizing the potential for residual confounding from 
differences in the characteristics of women who use this form of contraception as compared 
to non-users.   
  61
We conducted additional sensitivity analyses to evaluate the potential for bias 
through loss to follow-up.  Pregnancies with exposure to a hormonal contraceptive within the 
first 12 weeks after the estimated date of conception were more likely to have been lost to 
follow-up than pregnancies with no exposure (Appendix, Supplementary Table S4.3).  
However there was no evidence of any pattern in the missing data whereby a covariate or 
set of covariates could predict the pattern of missingness.  We used a multiple imputation 
approach(82) (SAS PROC MI - Monte Carlo Multiple Chain) to impute 10 data sets with 
imputed follow-up data for offspring BMI.  Imputation models were richly constructed and 
included all of the study covariates, study exposures, study outcomes, offspring birthweight 
and length, offspring sex, pregnancy intendedness, and gestational age at birth.  We 
modeled the association between hormonal contraceptive exposure and offspring 
overweight or obesity for each of the imputed datasets.  The model results for each data set 
were then synthesized to obtain final estimates for the multiple imputation approach (SAS 
PROC MIANALYZE).   
As an alternative approach to multiple imputation, we also conducted a sensitivity 
analysis using inverse probability weighting to account for loss to follow-up.  To do this, we 
constructed weights based on the inverse of the predicted probability of staying in the study, 
i.e., up-weighing those with a high probability of being lost to follow-up.  These inverse 
probability weights were scaled by multiplying the weights by the marginal probability of 
staying in the study.(83)     
4.3 Results 
In general, compared to all MoBa pregnancies with baseline data collected in 
pregnancy and at birth, the pregnancies included in the final study sample were to women 
who were older, slightly less parous, slightly less likely to have smoked in pregnancy, and 
slightly more educated (Table 4.1).   
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Table 4.1: Study and baseline population characteristics among women 
participating in the Norwegian Mother Child Prospective Cohort Study 
(2004-2008)  
 Baseline population Study population  
  n=44,649 n=19,652 
  % % 
Maternal age (years)   
14-19 0.9 0.4 
20-29 42.1 40.3 
30-39 54.9 57.1 
40-49 2.1 2.3 
Maternal BMI (kg/m2)   
<18.5  3.2 2.9 
18.5-24.9 66.1 67.2 
25.0-29.9 21.7 21.8 
≥30.0  9.0 8.1 
Parity   
0 47.1 50.0 
1 35.5 34.3 
2 13.7 12.4 
3 2.8 2.4 
4 or more 0.9 0.8 
Maternal education   
More than 4 years of university or technical 27.2 29.9 
4 year university degree, regional technical 40.8 43.9 
3 years high school, junior college 13.5 12.0 
Technical high school 11.2 9.3 
1-2 years high school 3.9 2.6 
9-year secondary 2.2 1.1 
Other 1.4 1.4 
Maternal smoking (at 17 weeks)   
None 79.3 82.8 
Quit 14.5 12.6 
Daily  1.4 1.2 
Sometimes 4.8 3.4 
*Represents unique pregnancies with no use of IVF treatment, resulting in a singleton live birth and no 
death in the first year of life, with a date of birth >=12 months after NorPD registry began (January 1, 
2004) 
 
At 36 months of age, 2,653 (13.1%) children in the study sample met the IOTF 
definitions for overweight or obese.  Linkage to the NorPD identified 9,675 (48.6%) women 
with a prescribed hormonal contraceptive within 12 months prior, 6,132 (31.0%) within 4 
months prior, 3,469 (17.6%) within 1 month prior, and 567 (2.9%) within 12 weeks after 
conception.  Characterizing hormonal contraceptive use into discrete exposure windows, 
described according to last use, identified 3,392 exposed pregnancies within 12 months 
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before, 2,541 exposed pregnancies within 4 months before, 2,997 exposed pregnancies 
within 1 month before, and 567 exposed pregnancies within 12 weeks after conception.   
Primary analyses 
In early pregnancy, the combination oral contraceptive was weakly, inversely 
associated with offspring overweight or obesity at age 3.  The progestin-only oral 
contraceptive was weakly, positively associated with overweight or obesity (Table 4.2).   
Table 4.2. Association between hormonal contraceptive use in early pregnancy* 
and offspring overweight or obese in the Norwegian Mother Child Prospective 
Cohort Study (2004-2008) 
Exposure  Exposed (n) 
Overweight 
or obese (n) 




None† 9,987 1,342 referent referent 
Combination OC 380 38 0.72 (0.51, 1.01) 0.75 (0.53, 1.08) 
Progestin-only OC 127 21 1.28 (0.80, 2.05) 1.26 (0.79, 2.02) 
Other‡ 60 7 0.85 (0.39, 1.88) 0.88 (0.40, 1.94) 
*Use within 12 weeks after conception as compared to no use of a hormonal contraceptive within the discrete 
categories of within12, 4, and 1 month before conception and within 12 weeks after conception 
**Adjusted for maternal age, maternal smoking at 17 weeks gestation, maternal pre-pregnancy BMI, and parity 
†No use of a hormonal contraceptive within the discrete categories of within12, 4, and 1 month before 
conception and within 12 weeks after conception 
‡Hormonal contraceptives with < 10 exposed cases were combined into an “other” category 
 
Use of a hormonal contraceptive prior to pregnancy was generally not associated 
with overweight or obesity at age 3, with the exception of use of a vaginal ring-type 
hormonal contraceptive, which was inversely associated with offspring overweight or obesity 
at age 3, particularly for exposure estimated to have occurred within 1 month of conception 
(Appendix, Supplementary Tables S4.4-S4.6).  Data were too sparse to evaluate the 
association between early pregnancy use of the vaginal ring and subsequent offspring 
overweight or obesity.   
Subgroup analyses 
Among combination oral contraceptive users, the association with overweight or 
obesity was similar across combination oral contraceptives with differing progestin 
components (Appendix, Supplementary Tables S4.7-S4.10).  In early pregnancy only, the 
desogestrel progestin-only oral contraceptive was moderately associated with offspring 
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overweight or obesity (aOR: 1.87, 95% CI: 1.06, 3.32) (Appendix, Supplementary Table 
S4.7). 
There was little evidence of effect modification by offspring sex or maternal pre-
pregnancy BMI.  However, for exposure to the combination oral contraceptive in early 
pregnancy, the observed association with overweight or obesity was present only in males 
(aOR: 0.56, 95% CI: 0.32, 0.97 in males vs aOR: 0.98, 95% CI: 0.63, 1.53 in females).  
Sensitivity analyses 
In early pregnancy, for the analyses evaluating the use of different comparator 
groups, the inverse association between the combination oral contraceptive and offspring 
overweight or obesity was robust to restricting the comparator population to only unplanned 
pregnancies.  This inverse relationship was also qualitatively unchanged when comparing 
early pregnancy combination oral contraceptive users to former users of the combination 
oral contraceptive and when comparing the combination oral contraceptive users to the 
progestin-only oral contraceptive users.  Similarly, the relationship between progestin use in 




Table 4.3. Sensitivity analyses for early pregnancy exposure to oral 
contraceptives and overweight or obesity in the Norwegian Mother Child 
Prospective Cohort Study (2004-2008) 
  n OR (95% CI) 
Adjusted** OR 
(95% CI) 
Approach 1: Compared to former users 
Combination OC       
former* user of Combination OC 6,146 referent referent 
**early pregnancy Combination OC user 380 0.76 (0.54, 1.07) 0.75 (0.52, 1.06) 
Progestin-only OC       
former* user of Progestin OC 1,962 referent referent 
*early pregnancy Progestin OC user 127 1.20 (0.74, 1.94) 1.24 (0.75, 2.04) 
 
Approach 2: Compared to unplanned pregnancies 
No hormonal contraception† 2,264 referent referent 
Combination OC 380 0.67 (0.46, 0.96) 0.70 (0.48, 1.02) 
Progestin-only OC 127 1.19 (0.73, 1.93) 1.22 (0.75, 1.98) 
Other‡ 60 0.79 (0.36, 1.76) 0.79 (0.35, 1.78) 
 
Approach 3: Compared to other oral hormonal contraceptive users 
Progestin-only OC 127 referent referent 
Combination OC 380 0.46 (0.23, 0.91) 0.56 (0.32, 1.00) 
*Former use defined as within 12 months but not within 4 months or 1 month of conception and early defined as 
within 12 weeks of conception 
**Adjusted for maternal age, maternal smoking at 17 weeks gestation, maternal pre-pregnancy BMI, and parity 
†No use of a hormonal contraceptive within the discrete categories of within 12, 4, and 1 month before 
conception and within 12 weeks after conception 
‡Hormonal contraceptives with < 10 exposed cases were combined into an “other” category 
 
The estimate comparing vaginal ring use to the combination oral contraceptive 
(within 1 month prior to conception) was aOR 0.59 (95% CI: 0.33, 1.03) and consistent with 
estimates obtained when comparing vaginal ring users to non-users of a hormonal 
contraceptive.  
Estimates from models employing multiple imputation or inverse probability 
weighting, to evaluate the potential for bias resulting from loss to follow-up at age 3, were 
qualitatively similar to those obtained in the primary analyses (Appendix, Supplementary 
Tables S4.11-S4.12).    
4.4 Discussion 
In our primary analysis of the association between early pregnancy hormonal 
contraceptive use and offspring overweight or obesity at age 3, we found that use of a 
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combination oral contraceptive was weakly, inversely associated with offspring overweight 
or obesity at age 3. Use of the progestin-only oral contraceptive in early pregnancy was 
weakly, positively associated with offspring overweight or obesity.  A moderate association 
for early pregnancy progestin-only oral contraceptive use was observed when examining the 
desogestrel form of the progestin-only oral contraceptive.  For exposure to hormonal 
contraceptives before pregnancy, there was an inverse association between use of the 
vaginal ring and overweight or obesity.  All of the associations were qualitatively unchanged 
with selection of different comparators groups.  Observed associations were robust to 
sensitivity analyses employing approaches for evaluating the potential for bias as a result of 
loss to follow-up.   
In experimental animal models, in utero and neonatal exposure to estrogenic agents 
(DES and 17β-estradiol) results in an initial period of depressed growth, followed by 
increasing adiposity at follow-up.(39, 40)  The weak, inverse association with the 
combination pill in the present study may be congruent with observations of an initial period 
of depressed growth in these experimental studies.  Follow-up of the MoBa cohort could 
allow investigation of associations at later ages to determine whether the growth pattern 
exhibited in animal models is relevant in humans.   
Not surprisingly, we observed differences in association depending on the type of 
contraceptive and progestin used.  The androgen, progestogen, and estrogen receptor 
binding affinities of the agents in different contraceptives vary.  Some exert androgenic 
properties, others antiandrogenic properties.(87)  Variability in pharmacokinetics, for 
different formulations of hormonal contraceptives, and also between women, impacts 
activity.  Unlike many medications that are titrated to the weight of the individual, each 
hormonal contraceptive formulation is prescribed at the same dose, irrespective of body 
weight.    
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To our knowledge, studies of offspring adiposity or growth following exposure to 
progestogenic compounds during early fetal development have not been conducted in 
animals or humans.  However, endogenous serum progesterone levels in both early and 
mid-pregnancy have been positively associated with offspring birthweight(107, 108) and 
birthweight has been associated with offspring weight at follow-up.(109)  Fetal exposure to 
androgenic agents has resulted in metabolic abnormalities, including a polycystic ovarian 
syndrome-like phenotype in animal models.(99)  When unopposed by ethinyl estradiol, 
desogestrel has high progestational and moderate androgenic activity relative to other 
progestin types, but when desogestrel is present in combination with ethinyl estradiol, the 
progestational and androgenic activities are substantively reduced.(87)  Norethisterone is 
only weakly androgenic.  This property may explain, in part, the difference in association 
observed between desogestrel and norethisterone progestin-only contraceptives in this 
study. 
Given the positive association between the combination oral contraceptive and 
offspring overweight or obesity, the inverse association for the vaginal ring contraceptive 
was surprising.  The inverse association between use of the vaginal ring and offspring 
overweight or obesity may be attributable to the pharmacokinetic properties of the vaginal 
ring.  The vaginal ring contains etonogestrel and ethinyl estradiol.  Hormonal constituents of 
the vaginal ring are absorbed through the vaginal epithelium and provide daily, slow release 
of etonogestrel and ethinyl estradiol for the three week period after the ring is inserted.(87)  
Pharmacokinetic studies comparing the vaginal ring to the combination oral contraceptive 
indicate that the dose of ethinyl estradiol, as measured in blood serum and represented by 
the area under the curve, is lower than that of doses experienced in combination oral 
contraceptive users.(110)  The agents in the vaginal ring do not experience first pass 
metabolism.  The ring provides a consistent release of hormones unaffected by dietary or 
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gastrointestinal factors and is less subject to fluctuation in delivered dose when compared to 
oral or transdermal-administered forms of contraception.(111, 112)  
Sparse data limited the ability to assess for variation in effects from different 
progestin types in early pregnancy.  With the exception of early pregnancy use of the 
combination oral contraceptive, we found little evidence of effect modification by offspring 
sex or maternal pre-pregnancy BMI.  Sample size limitations may have precluded the ability 
to detect effect modification.  The effect modification observed for early pregnancy is 
consistent with animal data suggesting that developmental effects of estrogenic compounds 
may be sex-specific, with stronger associations observed among male offspring.(40)   
The associations observed for the combination oral contraceptive, progestin-only oral 
contraceptive, or vaginal ring contraceptive could be attributable to residual confounding or 
confounding by indication.  Women may be prescribed different contraceptive formulations 
based on factors for which we cannot control in our data.  Notwithstanding, estimates 
obtained from comparator group sensitivity analyses, conducted to assess the potential for 
confounding by indication, were robust to choice of comparator group selection.   
Magnitude of estimates was also robust to loss to follow-up, based on two separate 
strategies to explore the potential bias.  However, these strategies are effective only insofar 
as we have correctly assumed that we were able to successfully impute missing values from 
the covariates in our imputation models (multiple imputation approach) or correctly predicted 
the probability of staying in the study from the covariates in our models for generating 
weights (inverse probability weighting approach).   
There is also the potential for misclassification of exposure.  We characterized 
exposure using registry-based data for prescription fills of hormonal contraceptives and, for 
early pregnancy, indication that the pregnancy was unplanned, but this is an imperfect 
measure of true exposure.  Women may have been inconsistently taking the contraceptive 
or may have had some other concomitant factor leading to contraceptive failure that 
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explains the associations observed.  Finally, while the registry data provides detailed 
information on formulation and doses, it cannot provide any account of actual use of the 
contraceptive.  In early pregnancy, women were only characterized as exposed if they 
reported the pregnancy was unplanned.  Our assumption is that women with unplanned 
pregnancies were more likely to have been using the form of contraception documented in 
the registry at the time of conception.    
Lastly, it is possible that the height and weight data reported on the questionnaire 
were inaccurate.  Although women are instructed to record the height and weight data 
obtained by clinical staff at the time of the 3-year health exam, most of the study population 
reported that the measurements obtained were collected from their own measurements of 
height and weight.  However, the overall proportion of overweight or obese children at age 3 
in this study (13.1%), as identified by these maternal-reported height and weight measures, 
is relatively consistent with national prevalence estimates for overweight or obesity at age 3 
that were obtained from height and weight data collected by research staff (11.3%).(4)   
Finally, we were only able to evaluate associations with children at age 3.  Some of 
the animal model literature suggests that the association between hormonally active agents 
and offspring adiposity only becomes evident at later ages.(39, 40)  It may be that a similar 
study, in children at older ages, would identify stronger associations than those observed in 
the present analysis.  Furthermore, BMI is less specific for identifying adiposity in children 
when compared to other measures of assessing childhood adiposity.  Higher BMI may 
reflect increased muscle mass, as opposed to increased fat mass.(113, 114)     
This study builds on experimental animal data suggesting that overweight and 
obesity may be rooted in developmental insults from exogenous sex hormone exposure in 
early life.  These data suggest that pharmacologic sex hormone agents may be associated 
with offspring overweight or obesity at age 3.  The direction of the relationships appears 
contingent upon hormone formulation.  This area of research is in its infancy, but provides 
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the rationale for additional investigation exploring these associations.  Hormonal 
contraceptive use is prevalent, yet little is known about long-term, formulation-specific 
effects on offspring.
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CHAPTER 5: CONCLUSION 
 
5.1 Summary of results 
We assessed the potential for exposure to pharmacologic sex hormones, conferred 
through use of hormonal contraceptives, to exert effects on offspring growth and 
development.  Specifically, we evaluated whether use of a hormonal contraceptive, up to 12 
months before and within 12 weeks after conception, was associated with gestational length 
at birth, preterm birth, weight for gestational age z-score, small for gestational age, body 
mass index z-score, and overweight or obesity at age 3.   
We characterized use of hormonal contraceptive by type and route of administration, 
but also by progestin component.  In doing so, we advanced the current literature that is 
either limited to experimental animal data (primarily evaluating the association between 
estrogenic compounds and overweight or obesity) or to evaluation, in humans, of exposure 
to hormonal contraceptives characterized more broadly (e.g. oral contraceptives).  To our 
knowledge, there have been no studies exploring the potential for an association between a 
progestin-only oral contraceptive and indicators of altered growth and development in 
offspring.  Furthermore, there are no published studies examining hormonal contraceptives 
by specific progestin component.   
We identified an association between use of hormonal contraceptives and 
gestational length at birth and preterm birth and with BMI z-score and overweight or obesity 
at age 3.  The associations observed were specific to some forms of hormonal contraceptive 
and, in some instances, only to use during early pregnancy.  Specifically, use of a 
combination oral contraceptive, across all exposure periods, was associated with increased
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odds for birth.  The magnitude of the association differed by progestin component within the 
combination oral contraceptive.  Use of the norethisterone progestin-only oral contraceptive 
in early pregnancy was associated with preterm birth.  Use of medroxyprogesterone, found 
in the injectable type of hormonal contraceptive, was associated with preterm birth when 
used prior to pregnancy.  Data were too sparse to evaluate medroxyprogesterone use in 
early pregnancy.  There was no association between use of the transdermal hormonal 
contraceptive, containing norelgestromin, or vaginal ring hormonal contraceptive, containing 
etonogestrel, with preterm birth.   
We observed an inverse association between use of a progestin-only oral 
contraceptive and SGA, for use before pregnancy; however, sample size limitations 
precluded assessing the association by type of progestin used in the progestin-only oral 
contraceptive.  Small sample size also precluded evaluation of the association between use 
of the progestin-only oral contraceptive in early pregnancy.  No other associations between 
hormonal contraceptive use and SGA were observed.   
At age 3, we observed a positive association between early pregnancy use of a 
progestin-only oral contraceptive, specifically use of desogestrel, and overweight or obesity.  
Early pregnancy use of a combination oral contraceptive was inversely associated with 
overweight or obesity at age 3.  Use of the vaginal ring hormonal contraceptive, particularly 
in the month prior to conception, was inversely associated with overweight or obesity.   
Several different sensitivity analyses were conducted to assess the robustness of the 
study results given assumptions made in conducting the complete case analyses.  These 
included inverse probability weighting and multiple imputation to account for possible bias 
introduced through loss to follow-up, and also evaluation of the potential for residual 
confounding or confounding by indication by using different comparator groups and a 
propensity score analysis.  Generally, the magnitude of associations observed in the primary 
analyses was robust to these approaches.   
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To summarize, we observed a potential association between hormonal 
contraceptives and indicators of offspring growth and development.  The associations 
observed were dependent on the exposure period and formulation of contraceptive used.  
Overall, the strongest associations were observed for use in early pregnancy.  Interestingly, 
use of the combination oral contraceptive, in early pregnancy, was positively associated with 
preterm birth and inversely associated with overweight or obesity at age 3, suggesting the 
possibility that offspring exposed in utero may still be catching up in growth at age 3.  A 
longitudinal analysis could assess the growth patterns of exposed offspring to evaluate this 
question further.  Similarly, the progestin-only oral contraceptive, protective for SGA for use 
prior to pregnancy, was observed to be associated with overweight or obesity at age 3 for 
use in early pregnancy.  Small sample limitations precluded assessment of the progestin-
only oral contraceptive with SGA in early pregnancy, therefore a direct comparison, based 
on timing of exposure, was not possible.   
5.2 Limitations and strengths 
Limitations 
There are several important limitations to this research.  These limitations are 
inherent to pharmacoepidemiology research and observational research in general and 
include: 1) sparse data – specifically for evaluating specific drug formulations and the 
relatively rare outcomes of SGA and PTB,, 2) the potential for intractable confounding by 
indication, and 3) the potential for misclassification of both the exposure and outcome.  
Details of these limitations follow.   
Sample size limitations: 
An important limitation in this study was the sparse data for early pregnancy use of a 
hormonal contraceptive.  There was also sparse data for some of the less commonly used 
contraceptive formulations, such as the intrauterine device, implant and injectable, and for 
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some contraceptives of any type with certain progestin formulations.  Sparse data was most 
limiting for analyses of the association between hormonal contraceptive use and SGA.   
Insufficient sample sizes for some contraceptive formulations precluded comparisons 
across exposure periods for certain hormonal contraceptive types.  The inability to compare, 
across exposure periods, limited the ability to assess for differences in magnitude of 
association with respect to proximity to conception, but also differences between use of a 
particular progestin component between hormonal contraceptives of different types at the 
same exposure period.  Small sample limitations also made evaluation of possible effect 
measure modification difficult.  We assessed for effect modification by offspring sex and 
maternal pre-pregnancy overweight or obesity status.  Models assessing for potential effect 
measure modification for birth outcomes often failed to converge.  Ultimately, given the 
limitations of the data, we chose to only pursue presentation of effect medication when 
evaluating the association between hormonal contraceptive use and offspring overweight or 
obese.   
Confounding: 
Another important limitation to this study is the potential for intractable confounding, 
specifically, unmeasured or residual factors that may be antecedents of both hormonal 
contraceptive use of a particular type and offspring growth and development outcomes.  
Parity was identified as a significant confounder in the association in our models evaluating 
hormonal contraceptive use and preterm birth or SGA.  Maternal pre-pregnancy BMI was a 
significant confounder in our models evaluating the association between hormonal 
contraceptive use and offspring overweight or obesity at age 3.  We conducted sensitivity 
analyses with varying comparator groups to assess for possible residual confounding.  
Some of these approaches included restricting models to nulliparous pregnancies, 
comparing early pregnancy users to former users, restricting to unplanned pregnancies for 
associations observed in early pregnancy, and comparing users of one formulation to users 
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of a different formulation.  Generally, results were robust to these various approaches; 
however the potential for confounding is still possible.  For example, although in one of the 
sensitivity analyses we restricted the analysis to nulliparous pregnancies, there is the 
potential that there are factors related to prescription for the combination oral combination, 
as opposed to selecting a different form of contraceptive, which may be associated with 
preterm birth.  The underlying hormonal milieu of a woman can influence her tolerance for 
different forms of contraception and thus the type of hormonal contraceptive she is 
prescribed.  It has been hypothesized that these underlying factors potentially contribute to 
growth and development of the fetus.(25)  Women with a history of a previous preterm birth 
are often provided progestin therapy, starting in the second trimester of pregnancy, to 
reduce risk for a subsequent preterm delivery.(115)  These women are believed to have 
inadequate or premature signaling of parturition as indicated by declining progesterone 
levels.(116, 117) 
We also conducted a propensity score analysis whereby we modeled the probability 
of treatment (prescription for combination oral contraceptive use).  The propensity score 
analysis assumes that we have adequately modeled the probability of treatment using the 
covariates selected, and offers the opportunity to evaluate lack of common support for 
exposed and unexposed in the data.  However, propensity score approaches cannot offer 
improved control of confounding for potential unobserved factors predictive of treatment and 
offspring anthropometric indicators.  As with analyses employing use of different comparator 
groups, the assumption is that there is no unmeasured or unaccounted confounding 
remaining.   
We observed a relatively consistent effect estimate when modeling the association 
between the combination oral contraceptive and preterm birth.  Such an observation could 
be an indication of residual or unaccounted confounding.  Alternatively, it could also be 
indicative of association between combination oral contraceptives used long term and 
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preterm birth.  It is also possible that the hormonal contraceptives are operating 
independently at each of the exposure periods and that, by chance, the estimates were 
qualitatively similar.  In other words, the combination oral contraceptive could be acting on 
each of the follicular, oocyte, and embryonic developmental stages in such a way as to 
disrupt the cascade of events leading to fetal signaling of parturition.   
Misclassification: 
Another limitation in this study is the potential for misclassification of exposure to 
hormonal contraceptives.  Although linkage to the NorPD registry offered the opportunity to 
explore exposures in much greater detail than has been described previously in the 
literature, use of prescription registry data is inherently limited in that it represents 
prescription data and not actual use.  Furthermore, in this study population, most 
prescriptions for hormonal contraceptives were provided in 3 month’s supply (82%).   Likely, 
the more days of supply provided, the greater the potential that a woman will have stopped 
taking the hormonal contraceptive before the last day supplied.   Obviously, the association 
between the injectable contraceptive and preterm birth would not be subject to this 
limitation.  Once the injectable is administered, the progestin (medroxyprogesterone) 
remains detectable (>100 pg/mL) for up to 200 days post-injection, although there are some 
women for whom the progestin levels have remained detachable for as long as 8 months 
post-injection.(118)  Peak values are reached much earlier, between 9 -21 days, depending 
on the dose administered, and women are advised to return for a repeat dose at 3 month 
intervals.(87) 
Self-reported data was limited in that it did not provide data distinguishing the type of 
oral contraceptive used within 4 months.  It also did not allow for exploring use within 1 
month of conception, a period of interest given the potential for developmental effects on the 
oocyte.  An assessment of agreement between self-report and NorPD-indicated use 
suggested moderate agreement between the two sources of data for any oral contraceptive 
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use (Kappa values: 0.45 for early pregnancy, 0.60 for exposure within 4 months, and 0.69 
for exposure within 12 months of conception).  Assessing agreement in more recent time 
periods, 24 or 36 months after NorPD implementation, had no effect on the degree of 
agreement between the two data sources.   
There was also the potential for misclassification of the outcome.  It is possible that 
the height and weight data reported on the questionnaire were inaccurate.  Although women 
are instructed to record the height and weight data obtained by clinical staff at the time of 
the 3-year health exam, most of the study population reported that the measurements 
obtained were collected from their own measurements of height and weight.  However, the 
overall proportion of overweight or obese children at age 3 in this study (13.1%), as 
identified by these maternal-reported height and weight measures, is relatively consistent 
with national prevalence estimates for overweight or obesity at age 3 that were obtained 
from height and weight data collected by research staff (11.3%).(4)  Our intention was to 
conduct a validation study of height and weight, comparing the height and weight data 
reported on the MoBa questionnaire to data collected in the Bergen Growth Study.  
Unfortunately, there were numerous delays in obtaining the data for completing this 
validation study, in part because of insufficient number of children represented in both the 
Bergen Growth Study(119) and the MoBa cohort.  Because the sample size was determined 
too be too small, we requested height and weight data for children represented in both 
studies for ages 6 and 18 months also.  This validation work is on-going and it has yet to be 
determined whether there will be a sufficient sample from which a validation study can be 
completed.    
Still, another concern is the lack of specificity in using BMI for identifying clinically 
relevant adiposity in children when compared to other measures of assessing childhood 
adiposity.(113, 114)  Higher BMI can be indicative of higher muscle mass, as opposed to fat 
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mass, particularly for children identified as overweight, but not obese.  Our sample size 
limitations precluded assessing associations with obesity only.   
Finally, we were only able to evaluate associations with children at age 3.  Some of 
the animal model literature suggests that the association between hormonally active agents 
and offspring adiposity only becomes evident at later ages.(39, 40)  We observed a 
stronger, and inverse magnitude of an association between hormonal contraceptive use and 
anthropometric indicators at birth.  Associations were attenuated or null at age 3.  This 
pattern may reflect the pattern observed in the animal literature suggestive of an inverse 
association at birth, followed by a period of catch-up growth whereby the exposed and 
unexposed are similar in weight, and then, later in life whereby exposed exceed the controls 
in fat mass.(39)   
Selection bias: 
The potential for selection bias was an important limitation in our evaluation of the 
possible association between hormonal contraceptive use and offspring overweight or 
obesity.  Overall, 44% of the study population was lost to follow-up at age 3.  Among 
hormonal contraceptive users, the loss to follow-up was similar, with one exception.  When 
compared to non-users, a slightly higher proportion of women characterized as early 
pregnancy hormonal contraceptive users were lost to follow-up, when compared to non-
users (Appendix, Supplementary Table S4.3).    
We used two approaches to evaluate the potential for selection bias; 1) multiple 
imputation to impute missing measurements at age 3, and 2) an inverse probability 
weighting approach whereby we assigned weights to those staying in the study, up-
weighting those who remained in the study but who had the same characteristics of those 
who left the study early.  The estimates from these approaches were qualitatively similar, 
and similar to the estimates obtained in the complete case analysis.  The comparability of 
the estimates obtained provides support for the results obtained in the complete case 
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analysis, but with the caveat that there is the potential that we did not include important 
covariates in our imputation model or in our model predicting study follow-up.   Both of these 
approaches assume that missing data are missing at random and that factors related to 
missingness have been accounted for in the modeling approaches.  In this study, there is 
little evidence to suggest otherwise; the covariate distribution of those who remained in the 
study is similar to the distribution of covariates for women who met study inclusion criteria 
(Table 4.1).  
Strengths 
There are several notable strengths to this research.  This is a novel study that 
translates ideas that have been explored in animal data into observational human research, 
specifically evaluating the potential for pre- and early post-conception exposure to 
exogenous sex hormones to act as obesogens for offspring.   
Although there is some literature assessing the potential for adverse effects for birth 
outcomes, as a result of hormonal contraceptive use, this literature is limited by relatively 
small sample sizes and crude estimation of exposure.  The present study is the first study to 
explore associations between hormonal contraceptive use and birth outcomes, defining 
hormonal contraceptive use by type, route, and progestin component.   
The MoBa study cohort is a relatively homogenous population.  Although this could 
have implications for generalizability of study results to other populations, this relative 
homogeneity provides the opportunity to study exposure outcome associations with a 
reduced potential for confounding.   
Although our sample size was too small to estimate some associations, particularly 
for less commonly used formulations, we did have sufficient data to explore the use of 
multiple comparator groups and to employ a variety of methods to assess the robustness of 
the study results given the potential for threats to study validity.  The greatest threat to 
validity was the potential for residual confounding.  Results were generally insensitive to 
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choice of comparator group or to analyses employing a propensity score analysis approach 
in the evaluation of combination oral contraceptive use and odds of preterm birth.  
5.3 Additional analyses 
Characterizing timing of exposure 
There were additional analyses conducted in this study that are not reflected in 
Chapters 3 and 4 of this document.  These analyses primarily concerned approaches to 
characterizing the use of hormonal contraceptives.  Initially, we characterized exposure 
according to any use within 12, 4, or 1 month before conception and any use within 12 
weeks after conception.  The referent group for this analysis was non-users of a hormonal 
contraceptive for the exposure period of interest.  Each period of exposure was modeled 
separately.  In this approach, the windows of exposure were nested within one another.  For 
example, users of a hormonal contraceptive within 1 month would also be included in the 
characterization of use within 4 months and 12 months.  A limitation in using this approach 
was the inability to differentiate associations observed in one period of exposure from 
another period of exposure.  Any association observed within 4 months could be an 
indication of an association between exposure in the 1 month before or in the 12 weeks after 
conception, or in the period between 4 and 1 month prior to conception.  This approach 
limited our ability to assess for differences of association across time or evaluation of any 
“dose response” as the exposure period approached and surpassed the estimated date of 
conception.  
Seeking to address the limitations of the approach described above, we re-
characterized exposure into discrete exposure periods – discrete in that they represented 
the window of time in which the last dose of contraceptive would have been taken.  
Furthermore, we limited our comparator group to non-users of hormonal contraceptives 
within any of the exposure periods.  In doing so, we could assess whether there were 
differences in association based on the exposure period, relative to the date of conception, 
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as compared to unexposed pregnancies.  By not including users of hormonal contraceptives 
in other exposure periods, we answered the question of whether or not use of a hormonal 
contraceptive, in a given exposure period, relative to non-users, confers increased odds for 
a given outcome.  Contrasting use against non-users for that exposure period answered a 
different question; specifically, does use of a hormonal contraceptive in a given period of 
time, relative to non-users in that period of time, incur increased odds for a given outcome. 
While this provided more information about timing of use, this approach offered less 
information about whether use, in general, confers increased odds for the outcomes of 
interest.   
Last date of use 
In characterizing exposure, we based the last date of possible use according to the 
number of daily doses dispensed, adding this number to the date on which the prescription 
was dispensed.  In doing so, we assumed that the use of the drug began on the day on 
which it was prescribed.  To evaluate this assumption, we calculated the mode, median, and 
mean for the difference in days between the last dose date and next dispensing date for 
serial dispensing of the same type of hormonal contraceptive (oral combination, oral 
progestin-only, vaginal ring, transdermal, and injectable).  The mean distribution was not 
distributed normally as there were some women who had long breaks between dispensing.  
Based on the median and mode, we determined that the assumption that the last dose date, 
as estimated by the number of DDDs dispensed, provided a reasonable approximation of 
the last day on which the drug could have been taken.  Specifically, for the vaginal ring, the 
mode difference was -1 days and the median difference was -2 days, representing that 
women commonly were dispensed a subsequent prescription for the vaginal ring within 1 to 
2 days after the final dose of the preceding dispense.  The mode and median difference for 
all other forms of hormonal contraceptives was 0 days.  
  82
Self reported exposure 
We also considered using self-reported use of hormonal contraceptives to define our 
exposure.  However, as described previously, this approach had the limitation of not being 
able to characterize use by formulation and within periods of time closer to conception (only 
within 12 months and after conception were women asked to differentiate between 
combination and progestin-only oral contraceptives).  There was also the potential that 
women would not be able to accurately recall or know whether the formulation of hormonal 
contraceptive they were using was a progestin-only or combination type oral contraceptive.  
We assessed the distribution of study covariates by self-reported use and saw that the 
distribution was inconsistent with the empirical data on prescribing patterns for different 
contraceptive formulations (Table 5.1).(87) 
Table 5.1. Distribution of study covariates by self-reported use of hormonal 
contraceptives 
Number exposed  
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For example, the progestin-only oral contraceptive is more commonly prescribed to 
older women and women who smoke.  The combination oral contraceptive is 
contraindicated for women over the age of 35 who smoke.  The progestin-only oral 
contraceptive is also more likely to be prescribed to women who are parous, as it is believed 
that the progestin-only oral contraceptive will not interfere with the milk supply of 
breastfeeding mothers.(87)  The NorPD-characterized hormonal contraceptive was more 
consistent with the expected prescribing patterns (Appendix, Supplementary Table S3.1). 
5.4 Future directions 
In the present study we identified a positive association between the combination 
hormonal contraceptive and preterm birth and an inverse association between the progestin-
only oral contraceptive and small for gestational age.  At age 3, there was evidence of an 
inverse association between combination oral contraceptive use and overweight or obesity 
and a positive association between use of a progestin-only oral contraceptive and 
overweight or obesity.  It may be that the infants born preterm continue to be smaller at age 
3 and that the infants at less risk for having been born SGA are larger at age 3.  Modeling 
these associations to assess differences in longitudinal growth patterns in early life could 
help identify whether there are differences in growth from hormonal exposures that begin 
during these developmentally sensitive periods.  Given the literature suggesting that being 
born small or early may be associated with future metabolic syndrome, additional studies 
exploring growth trajectories into school-aged and adolescent children may prove 
informative. 
Despite the large sample size of the present study, future studies exploring these 
associations could benefit from an even larger study cohort sample size to estimate 
associations with greater precision and to model associations for formulations that were less 
commonly used in this cohort.  Prescription, birth registry, and birth cohort data collected in 
  84
Denmark could offer the opportunity to explore these associations in a larger cohort.  For 
evaluation of the association between hormonal contraceptives and birth outcomes, linkage 
to the Danish National Birth Cohort (DNBC) study would offer a sample of approximately 
97,000 births.  Linkage to the DNBC study would offer about 57,000 children at age 7, 
roughly twice that of the sample in the present study, for evaluation of the association 
between hormonal contraceptive use and offspring overweight or obesity.  The DNBC study 
is also conducting follow-up with children once they reach age 11, thus providing the 
opportunity for assessing potential long-term effects of hormonal contraceptive use on 
offspring growth and development.   
To assess the possibility that the associations observed in this study represent 
unaddressed confounding, particularly confounding by indication, studies will need to be 
conducted on prescribing practices as they relate to maternal characteristics.  The present 
study described differences in maternal characteristics by type of hormonal contraceptive 
prescribed, but these differences should be described by specific formulation, including 
progestin component.  Furthermore, there may be other maternal characteristics that merit 
consideration, such as maternal menstrual cycle differences that may be predictive of the 
formulation of hormonal contraceptive prescribed.  These differences in menstrual cycles 
may suggest underlying differences in maternal metabolic milieu, a possible confounder in 
any relationships observed between hormonal contraceptive use and offspring 
developmental outcomes.    
5.5 Public health impact  
The primary implication of this research is the potential that hormonal contraceptive 
use, for some types and formulations, may be associated with adverse pregnancy outcomes 
and altered growth and development of offspring.  For offspring overweight and obesity, the 
association observed was strongest for exposure in early pregnancy.   Exposure in early 
pregnancy is relatively uncommon; however the potential that hormonally active agents 
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could be associated with offspring development is informative to other research, such as the 
potential for environmental sources of exposure to hormonally active agents to confer 
developmental effects on offspring.  Much of the literature on potential developmental 
effects of exposure to exogenous, hormonally active agents is confined to animal model 
data.  This research translates what has been demonstrated in experimental data into 
observational, human research and supports the assertion that developmental effects from 
these exposures are possible.   
This research may also be informative to research on other pharmacologic sex 
hormone agents.  There are other, commonly used, pregnancy-related pharmacologic sex 
hormones, such as hormonal agents in infertility treatment or for prevention of preterm birth.  
The results of this research suggest we should assess the potential for long-term 
developmental effects of these agents. 
For preterm birth, associations were observed for users of certain hormonal 
contraceptives during early pregnancy, but also before conception.  Assuming that other 
studies can offer additional assessment of the potential for confounding by indication and 
replicate the current findings, this research may have implications for prescribing practices.  
For women who may be planning a pregnancy, some contraceptive formulations may offer 
less of a potential for developmental effects to offspring.   
This area of research is in its infancy, but provides the rationale for additional 
investigation exploring these associations.  Hormonal contraceptive use is prevalent, yet 








Table S3.1. Study population characteristics by type of hormonal contraceptive used within 12* months before 
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 n=23,727 n=14,012 n=4,572 n=1,215 n=832 n=376 
Characteristic  % % % % % % 
Maternal age       
14-19 0.5 1.8 0.3 0.6 1.2 0.0 
20-29 33.1 56.5 37.7 54.3 59.0 47.9 
30-39 63.1 41.3 60.6 44.0 39.4 49.7 
40-49 3.3 0.4 1.4 1.1 0.5 2.4 
Maternal BMI (kg/m2)       
<18.5  3.3 3.1 3.3 2.8 4.1 2.9 
18.5-24.9 65.6 66.8 65.7 68.8 65.0 60.1 
25.0-29.9 21.3 21.9 22.8 22.6 21.3 28.2 
≥30.0  9.8 8.2 8.3 5.8 9.6 8.8 
Parity       
0 37.8 70.6 17.2 67.4 57.2 29.5 
1 39.6 20.9 63.9 21.0 27.5 41.2 
2 17.6 7.0 15.0 9.3 12.7 21.8 
3 3.8 1.1 3.1 1.7 1.9 5.3 
4 or more 1.3 0.4 0.8 0.7 0.6 2.1 
Maternal education       
More than 4 years of university or technical 29.5 23.4 30.0 25.8 16.4 17.8 
4 year university degree, regional technical 40.0 40.5 44.7 46.0 42.0 33.8 
3 years high school, junior college 12.7 15.3 10.6 13.2 17.7 17.3 
Technical high school 10.3 12.8 9.5 10.5 14.7 16.8 
1-2 years high school 3.9 4.3 2.8 2.1 4.9 7.5 
9-year secondary 2.3 2.3 1.3 1.1 2.6 5.3 
Other 1.4 1.4 1.2 1.4 1.8 1.6 
Maternal smoking (at 17 weeks)       
None 80.0 76.8 85.0 77.8 75.0 70.5 
Quit 13.9 16.5 10.9 16.5 16.6 18.6 
Daily  1.3 1.6 1.2 1.7 2.2 2.4 
Sometimes 4.8 5.1 3.0 4.1 6.3 8.5 
*Defined by any hormonal contraceptive use within 12 months prior to conception 






Table S3.2. Covariate balance by combination oral contraceptive use within decile rank for exposure within 12 
months before conception 
 Propensity score decile rank 





















Covariate No Yes No Yes No Yes No Yes No Yes No Yes No Yes No Yes No Yes No Yes 
Maternal age (yrs) 
14-19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.3 0.0 0.0 0.0 0.0 0.3 0.1 3.8 5.4 
20-29 0.0 0.0 0.2 0.6 1.7 4.0 11.6 9.1 49.1 50.5 71.2 68.8 2.6 4.6 2.6 4.6 43.0 42.0 96.2 96.4 
30-39 81.5 87.2 99.0 99.4 97.0 94.0 86.6 89.0 49.4 48.3 28.5 30.9 97.4 95.4 97.4 95.4 56.8 57.9 0.1 0.2 
40-49 18.5 12.8 1.2 0.0 1.3 2.0 1.8 1.8 1.5 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Maternal BMI (kg/m2) 
<18.5  3.8 4.3 3.3 2.9 3.6 5.5 2.6 3.2 2.3 2.8 1.5 1.7 5.7 5.5 5.7 5.5 5.6 5.1 0.5 0.8 
18.5-24.9 62.9 65.0 66.1 55.4 65.1 55.3 66.4 64.4 63.0 57.7 59.9 61.5 70.3 71.9 70.3 71.9 72.5 73.0 65.0 61.1 
25.0-29.9 21.1 20.5 20.3 24.6 21.5 24.6 20.2 23.3 25.1 29.7 27.8 24.1 16.0 15.8 16.0 15.8 14.3 16.5 26.8 30.1 
≥30.0  12.2 10.3 10.2 17.1 9.8 14.6 10.8 9.1 9.4 9.8 10.9 12.8 8.0 6.8 8.0 6.8 7.6 5.4 7.7 8.0 
Parity 
0 0.6 0.0 1.2 0.0 1.4 2.0 1.9 1.8 2.8 4.7 28.1 30.3 100 100 100 100 100 100 100 100 
1 36.5 34.2 45.9 56.6 60.9 56.3 71.5 69.9 81.2 79.2 69.0 68.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
2 44.8 47.9 41.2 30.9 31.1 35.2 22.8 24.7 13.9 14.5 2.5 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
3 13.5 11.1 9.7 10.9 4.9 5.5 2.9 2.7 1.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
4 or more 4.7 6.8 2.2 1.7 1.7 1.0 1.0 0.9 1.0 1.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Maternal education 
More than 4 years 
of university  
41.3 32.5 39.0 28.0 37.5 27.1 29.9 24.7 16.3 14.2 15.7 18.4 50.9 51.9 50.9 51.9 41.4 45.4 16.0 20.6 
4 year university 
degree 
29.9 24.8 36.8 40.0 39.1 35.7 45.0 44.8 52.7 44.8 42.1 34.8 29.6 30.6 29.6 30.6 36.6 36.2 48.4 50.8 
3 years high school 11.7 20.5 10.1 13.7 10.0 13.1 11.3 12.8 13.9 16.7 14.4 15.3 9.9 9.8 9.9 9.8 10.4 9.9 15.2 14.5 
Technical high 
school 
8.0 8.6 7.3 6.9 6.1 10.1 8.4 10.5 11.5 15.8 21.0 23.0 4.3 3.8 4.3 3.8 4.5 4.0 10.5 7.5 
1-2 years high 
school 
4.9 9.4 3.5 6.9 3.7 8.0 3.0 3.7 3.0 5.4 4.1 5.1 2.1 0.8 2.1 0.8 2.8 1.3 4.5 2.0 
9-year secondary 2.7 4.3 2.3 4.0 2.1 4.0 1.4 1.4 1.5 2.2 1.7 1.7 1.5 1.6 1.5 1.6 2.0 1.5 3.9 2.8 
Other 1.6 0.0 1.1 0.6 1.4 2.0 1.1 2.3 1.1 1.0 0.9 1.7 1.7 1.6 1.7 1.6 2.3 1.8 1.6 2.0 
Maternal smoking (at 17 weeks) 
None 84.0 78.6 85.5 79.4 84.8 75.4 84.1 79.0 81.7 78.2 76.9 72.2 80.0 84.2 80.0 84.2 79.2 81.7 66.6 66.2 
Quit 9.6 16.2 9.6 12.6 10.5 14.6 10.9 12.8 12.6 15.8 15.3 17.3 15.5 12.5 15.5 12.5 16.7 14.1 22.6 23.5 
Daily  0.9 1.7 0.8 1.7 1.2 1.0 0.9 0.5 1.7 1.3 2.1 2.8 0.7 1.3 0.7 1.3 0.9 1.5 3.3 2.5 






Table S3.3. Hormonal contraceptive use and weight for gestational age at birth  





OR (95% CI) aOR* (95% CI)  β (95% CI) 
unadjusted 
β (95% CI) 
adjusted* 
None 23,421 605 referent referent  referent referent 
Within 12 weeks after 
conception 
       
Combination OC 1,062 42 1.55 (1.14, 2.13) 1.10 (0.78, 1.55)  0.20 (0.14, 0.27) 0.02 (-0.05, 0.09) 
Other ** 576 15 1.01 (0.60, 1.69) 1.02 (0.60, 1.73)  0.07 (-0.02, 0.17) 0.08 (0.01, 0.18) 
Within 1 month before 
pregnancy 
       
Combination OC 4,660 142 1.19 (0.98, 1.43) 0.96 (0.80, 1.17)  0.15 (0.12, 0.19) 0.01 (-0.03, 0.04) 
Progestin-only OC 1,204 14 0.44 (0.26, 0.76) 0.57 (0.33, 0.97)  -0.09 (-0.16, -0.03) -0.03 (-0.09, 0.03) 
Vaginal ring 356 11 1.20 (0.66, 2.20) 0.99 (0.54, 1.81)  0.07 (-0.05, 0.18) -0.09 (-0.20, 0.03) 
Other ** 245 3 0.47 (0.15, 1.46) 0.40 (0.13, 1.27)  0.09 (-0.05, 0.22) -0.001 (-0.13, 0.13) 
Within 4 months 
before pregnancy 
       
Combination OC 3,833 103 1.04 (0.84, 1.29) 0.82 (0.66, 1.02)  0.11 (0.07, 0.15) -0.05 (-0.08, 0.01) 
Progestin-only OC 1,284 11 0.33 (0.18, 0.59) 0.41 (0.22, 0.75)  -0.10 (-0.16, -0.04) -0.03 (-0.09, 0.03) 
Vaginal ring 352 16 1.80 (1.08, 2.98) 1.48 (0.88, 2.49)  0.15 (0.03, 0.28) 0.01 (-0.11, 0.14) 
Other ** 271 6 0.85 (0.38, 1.93) 0.73 (0.32, 1.68)  0.08 (-0.06, 0.21) 0.004 (-0.14, 0.13) 
Within 12 months 
before pregnancy 
       
Combination OC 4,633 147 1.24 (1.03, 1.48) 0.95 (0.79, 1.15)  0.12 (0.08, 0.15) -0.05 (-0.09, -0.01) 
Progestin-only OC 1,795 33 0.71 (0.50, 1.01) 0.95 (0.66, 1.36)  -0.08 (-0.13, -0.03) 0.01 (-0.04, 0.06) 
Vaginal ring 424 10 0.91 (0.48, 1.71) 0.76 (0.40, 1.42)  0.07 (-0.03, 0.17) -0.06 (-0.16, 0.03) 
Other ** 618 9 0.56 (0.29, 1.08) 0.52 (0.26, 1.01)  0.01 (-0.08, 0.10) -0.02 (-0.11, 0.06) 
*Adjusted for parity, maternal education, maternal pre-pregnancy BMI, maternal smoking, and maternal age at birth 
**Hormonal contraceptive types with <10 exposed cases collapsed into a single "other" category 
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Table S3.4. Hormonal contraceptive use by progestin type and route of 
administration and small for gestational age  
Exposure Exposed (n) SGA (n) OR (95% CI) aOR* (95% CI) 
None 23,421 605 referent referent 
Within 12 weeks after conception  
Combination OC     
drospirenone and EE 368 16 1.71 (1.03, 2.05) 1.24 (0.74, 2.08) 
levonorgestrel and EE 545 19 1.36 (0.86, 2.17) 0.96 (0.59, 1.56) 
Other** 725 22 1.18 (0.77, 1.82) 1.08 (0.69, 1.69) 
 
Within 1 month before conception  
Combination OC         
desogestrel and EE 295 10 1.32 (0.70, 2.50) 1.12 (0.59, 2.12) 
drospirenone and EE 1,472 36 0.95 (0.67, 1.33) 0.75 (0.53, 1.05) 
levonorgestrel and EE 2,521 82 1.27 (1.00, 1.60) 1.04 (0.82, 1.32) 
norethisterone and EE 372 14 1.47 (0.86, 2.53) 1.24 (0.72, 2.13) 
Vaginal ring         
etonogestrel and EE 356 11 1.20 (0.66, 2.20) 0.99 (0.54, 1.81) 
Other** 1,449 17 0.45 (0.28, 0.73) 0.53 (0.32, 0.86) 
 
Within 4 months before conception 
Combination OC         
drospirenone and EE 1,227 35 1.11 (0.78, 1.56) 0.88 (0.62, 1.25) 
levonorgestrel and EE 2,107 61 1.12 (0.86, 1.47) 0.89 (0.68, 1.17) 
Vaginal ring         
etonogestrel and EE 352 16 1.80 (1.08, 2.98) 1.48 (0.88, 2.49) 
Other** 2,054 24 0.45 (0.30, 0.67) 0.46 (0.31, 0.70) 
 
Within 12 months before conception  
Combination OC         
desogestrel and EE 215 12 2.23 (1.24, 4.01) 1.73 (0.96, 3.12) 
drospirenone and EE 1,475 43 1.13 (0.83, 1.55) 0.87 (0.63, 1.19) 
levonorgestrel and EE 2,605 82 1.23 (0.97, 1.55) 0.95 (0.74, 1.21) 
norethisterone and EE 338 10 1.15 (0.61, 2.17) 0.89 (0.47, 1.68) 
Progestin-only OC         
desogestrel 1,031 18 0.67 0.42, 1.08) 0.88 (0.55, 1.42) 
norethisterone 640 12 0.72 (0.40, 1.28) 1.01 (0.56, 1.81) 
Vaginal ring         
etonogestrel and EE 424 10 0.91 (0.48, 1.71) 0.76 (0.40, 1.42) 
Other** 742 12 0.62 (0.35, 1.10) 0.61 (0.34, 1.08) 
*Adjusted for parity, maternal education, maternal pre-pregnancy BMI, maternal smoking, and maternal age at 
birth 




Table S3.5. Sensitivity analysis for combination oral contraceptive use and 
preterm birth with restriction to nulliparous pregnancies  
 
















Exposure  aOR* (95% CI) aOR* (95% CI) aOR* (95% CI) aOR* (95% CI)
None referent referent referent referent
Combination OC 1.39 (1.02, 1.90) 1.22 (1.02, 1.47) 1.39 (1.15, 1.68) 1.16 (0.97, 1.39)
Progestin-only OC 2.21 (1.03, 4.73) 0.80 (0.41, 1.56) 1.26 (0.71, 2.23) 1.18 (0.68, 2.04)
Vaginal ring ** 0.53 (0.24, 1.21) 0.82 (0.42, 1.62) 0.63 (0.31, 1.27)
Transdermal ** ** ** 0.73 (0.32, 1.67)
Injectable ** ** ** 1.97 (0.89, 4.35)
Other** 0.49 (0.15, 1.59) 0.49 (0.15, 1.55) 0.71 (0.29, 1.74) †
*Adjusted for maternal education, maternal pre-pregnancy BMI, maternal smoking, and maternal age at birth 
**Hormonal contraceptive types with <10 exposed cases collapsed into a single "other" category 






Table S3.6. Sensitivity analysis for combination oral contraceptive and preterm birth with vaginal ring users as the 
comparator group  
 
Within 1 month before 
conception (n=5,099)
Within 4 months before 
conception (n=4,185)
Within 12 months before 
conception (n=5,057)
Exposure  OR (95% CI) aOR* (95% CI) OR (95% CI) aOR* (95% CI) OR (95% CI) aOR* (95% CI)
Vaginal ring referent referent referent referent referent referent
Combination OC 1.54 (0.89, 2.67) 1.55 (0.89, 2.71) 1.67 (0.92, 3.01) 1.72 (0.94, 3.15) 1.88 (1.05, 3.39) 1.78 (0.99, 3.21)
*Adjusted for parity, maternal education, maternal pre-pregnancy BMI, maternal smoking, and maternal age at birth
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Table S3.7. Sensitivity analysis for association between combination oral 
contraceptive use and preterm birth with propensity score analysis approach*  
 
















Exposure  aOR** (95% CI) aOR** (95% CI) aOR** (95% CI) aOR** (95% CI)
None referent referent referent referent
Combination OC 1.35 (1.02, 1.77) 1.17 (1.00, 1.37) 1.34 (1.14, 1.57) 1.24 (1.06, 1.45)
*Doubly robust approach with generalized estimation equation models including both the predicted probability of 
combination oral contraceptive use (modeled as an indicator variable for decile rank) and with adjustment for 
parity, maternal education, maternal pre-pregnancy BMI, maternal smoking, and maternal age at birth 





Table S4.1. Distribution of hormonal contraceptive use by exposure period 






















None** 8,645 1,342 8,645 1,342 8,645 1,342 8,645 1,342 
Combination OC                 
desogestrel and EE 25 5 116 17 87 8 88 13 
drospirenone and EE 112 15 579 88 486 58 608 77 
levonorgestrel and EE 177 18 1,024 164 864 137 1,113 154 
norethisterone and EE 28 0 153 17 116 20 126 33 
Progestin-only OC                 
desogestrel 53 15 266 49 331 43 395 67 
norethisterone 52 6 204 28 169 32 235 44 
lynestronol 1 0 7 2 8 2 33 5 
levonorgestrel  0 0 6 0 11 2 18 5 
Vaginal ring  
(etonogestrel and EE) 30 4 159 14 138 15 183 21 
Transdermal (norelgestromin 
and EE) 28 0 87 13 94 9 103 15 
Injectable                 
(medroxyprogestin) 3 0 1 0 9 2 55 10 
Implant (etonogestrel) 0 0 0 0 0 0 7 0 
IUD (levonorgestrel) 3 0 3 0 3 0 44 5 
*Represents discrete categories of exposure based on the last possible date of use as derived from date of prescription and the defined daily doses prescribed  





Table S4.2. Covariate distribution by contraceptive formulation and route of administration for use at 
any time within 12 months of conception 






Vaginal Ring Transdermal Injectable 
 n=10,099 n=6,459 n=2,061 n=558 n=335 n=78 
Covariate  % % % % % % 
Maternal age       
14-19 0.2 0.7 0.2 0.0 0.6 0.0 
20-29 30.8 54.9 35.0 53.4 53.1 50.0 
30-39 65.3 43.9 63.6 45.3 46.3  48.7 
40-49 3.7 0.4 1.3 1.3 0.0 1.3 
Maternal BMI (kg/m2)       
<18.5  3.1 2.7 3.0 2.5 3.6 0.0 
18.5-24.9 66.6 68.2 67.2 67.6 66.3 61.5 
25.0-29.9 21.5 21.6 22.7 24.0 23.3 28.2 
≥30.0  8.9 7.5 7.1 5.9 6.9 10.3 
Parity       
0 39.9 73.7 18.5 73.3 60.3 52.6 
1 39.2 18.8 64.5 17.6 28.1 25.6 
2 16.4 6.1 13.7 7.7 10.8 19.2 
3 3.2 1.1 2.7 1.3 0.9 2.6 
4 or more 1.3 0.3 0.6 0.2 0.0 0.0 
Maternal education       
More than 4 years of university or 
technical 
32.2 26.6 31.8 27.6 19.7 16.7 
4 year university degree, regional 
technical 
42.4 43.3 47.6 49.8 50.2 38.5 
3 years high school, junior college 11.5 13.4 9.3 13.1 13.4 23.1 
Technical high school 8.4 11.3 7.8 7.2 10.5 15.4 
1-2 years high school 2.7 2.7 1.7 0.5 2.7  5.1 
9-year secondary 1.0 1.3 0.8 0.5 1.8 0.0 
Other 1.3 1.5 1.1 1.3 1.8 1.3 
Maternal smoking (at 17 weeks gestation)       
None 83.6 80.5 87.6 79.8 82.4 68.0 
Quit 12.1 14.2 9.2 14.9 10.8 20.5 
Daily  1.1 1.4 0.9 2.0 1.2 5.1 




Table S4.3. Distribution of hormonal contraceptive use for baseline population, study population, and proportion 
retained at follow-up 
*Represents the proportion of pregnancies retained at follow-up by contraceptive type – illustrates higher proportion lost to follow-up in early pregnancy among 
hormonal contraceptive users 
**Represents discrete categories of exposure based on the last possible date of use as derived from date of prescription and the defined daily doses prescribed 
†No use of a hormonal contraceptive within the discrete categories of within12, 4, and 1 month before conception and within 12 weeks after conception 
‡Includes intrauterine device, implant, and emergency contraceptive (for baseline population only) 
 




















































  Contraceptive  % % % %  % % % %  % % % % 
None† 75.8 80.3 78.4 93.5  74.3 79.1 76.9 94.6  42.7 42.7 42.7 42.7 
Combination OC  15.0 13.2 15.6 4.2  16.5 14.1 16.6 3.6  47.9 46.4 46.4 35.8 
Progestin OC 5.8 4.4 4.0 1.4  6.0 4.7 4.3 1.2  44.8 46.6 46.7 35.4 
Vaginal Ring 1.4 1.2 1.2 0.4  1.5 1.2 1.3 0.3  48.3 43.5 48.7 33.0 
Transdermal 1.0 0.8 0.8 0.4  0.9 0.8 0.8 0.2  40.3 44.0 42.2 22.7 
Injectable  0.6 0.1 0.0 0.0  0.5 0.1 0.0 0.0  36.1 42.3 33.3 75.0 




Table S4.4. Association between hormonal contraceptive use within 1 month* of conception and offspring 
overweight or obese 
Exposure  Exposed (n) 
Overweight or 
obese (n) Crude OR (95% CI) Adjusted** OR (95% CI) 
None 9,987 1,342 referent referent 
Combination OC 2,158 286 0.99 (0.86, 1.13) 1.04 (0.90, 1.19) 
Progestin-only OC 562 79 1.05 (0.83, 1.35) 1.03 (0.80, 1.31) 
Vaginal ring 173 14 0.57 (0.33, 0.98) 0.60 (0.35, 1.04) 
Transdermal 114 15 1.00 (0.58, 1.72) 1.03 (0.60, 1.77) 
Other† 4 0 ‡ ‡ 
*Use within 1 month before, but not within 12 weeks after conception as compared to no use of a hormonal contraceptive within the discrete categories  
of within12, 4, and 1 month before conception and within 12 weeks after conception 
**Adjusted for maternal age, maternal smoking at 17 weeks gestation, maternal pre-pregnancy BMI, and parity 
†Hormonal contraceptives with < 10 exposed cases were combined into an “other” category 






Table S4.5. Association between hormonal contraceptive use within 4 months* of conception and offspring 
overweight or obese 
Exposure  Exposed (n) 
Overweight or 
obese (n) Crude OR (95% CI) Adjusted** OR (95% CI) 
None 9,987 1,342 referent referent 
Combination OC 1,776 223 0.93 (0.79, 1.08) 0.96 (0.82, 1.13) 
Progestin-only OC 598 79 0.98 (0.77, 1.25) 0.97 (0.76, 1.24) 
Vaginal ring 153 15 0.70 (0.41, 1.20) 0.73 (0.43, 1.25) 
Other† 117 11 0.67 (0.36, 1.25) 0.67 (0.36, 1.26) 
*Use within 4 months before, but not within 1 month before and 12 weeks after conception as compared to no use of a hormonal contraceptive within the  
discrete categories of within12, 4, and 1 month before conception and within 12 weeks after conception 
**Adjusted for maternal age, maternal smoking at 17 weeks gestation, maternal pre-pregnancy BMI, and parity 





Table S4.6. Association between hormonal contraceptive use within 12 months* of conception and offspring 
overweight or obese 
Exposure  Exposed (n) 
Overweight or 
obese (n) Crude OR (95% CI) Adjusted** OR (95% CI) 
None 9,987 1,342 referent referent 
Combination OC 2,212 277 0.92 (0.80, 1.06) 0.98 (0.85, 1.13) 
Progestin-only OC 802 121 1.14 (0.94, 1.40) 1.12 (0.91, 1.37) 
Vaginal ring 204 21 0.74 (0.47, 1.16) 0.77 (0.49, 1.22) 
Transdermal 118 15 0.94 (0.51, 1.62) 1.01 (0.58, 1.74) 
Injectable 65 10 1.17 (0.60, 2.30) 1.14 (0.57, 2.26) 
Other† 56 5 0.63 (0.25, 1.59) 0.59 (0.24, 1.48) 
*Use within 12 months before, but not within 4 and 1 month before and 12 weeks after conception as compared to no use of a hormonal contraceptive within the 
discrete categories of within12, 4, and 1 month before conception and within 12 weeks after conception 
**Adjusted for maternal age, maternal smoking at 17 weeks gestation, maternal pre-pregnancy BMI, and parity 






Table S4.7. Association between hormonal contraceptive use in early pregnancy* and offspring 
overweight or obese by progestin type  
Exposure  Exposed (n) 
Overweight/o
bese (n) Crude OR (95% CI) Adjusted** OR (95% CI)  
None 9,987 1,342 referent referent  
Combination OC          
drospirenone and EE 127 15 0.86 (0.50, 1.48) 0.89 (0.52, 1.54)  
levonorgestrel and EE 195 18 0.66 (0.40, 1.07) 0.69 (0.42, 1.15)  
Progestin-only OC          
desogestrel 68 15 1.82 (1.03, 3.25) 1.87 (1.06, 3.32)  
Other†  143 14 0.70 (0.40, 1.22) 0.70 (0.40, 1.22)  
*Use within 12 weeks after conception as compared to no use of a hormonal contraceptive within the discrete categories of within 12, 4, and 
1 month before conception and within 12 weeks after conception 
**Adjusted for maternal age, maternal smoking at 17 weeks gestation, maternal pre-pregnancy BMI, and parity 







Table S4.8. Association between hormonal contraceptive use within 1 month prior to conception* and 
offspring overweight or obese by progestin type 
Exposure  Exposed (n) Overweight/obese (n) Crude OR (95% CI) Adjusted** OR (95% CI) 
None 9,987 1,342 referent referent 
Combination OC         
desogestrel and EE 133 17 0.94 (0.57, 1.58) 0.97 (0.58, 1.62) 
drospirenone and EE 667 88 0.98 (0.78, 1.23) 1.04 (0.82, 1.31) 
levonorgestrel and EE 1,188 164 1.03 (0.87, 1.23) 1.10 (0.92, 1.31) 
norethisterone and EE 170 17 0.72 (0.43, 1.19) 0.74 (0.45, 1.23) 
Progestin-only OC         
desogestrel 315 49 1.19 (0.87, 1.62) 1.16 (0.85, 1.59) 
norethisterone 232 28 0.88 (0.59, 1.32) 0.85 (0.57, 1.27) 
Vaginal ring         
etonogestrel and EE 173 14 0.57 (0.33, 0.98) 0.60 (0.35, 1.04) 
Transdermal     
norelgestromin and EE 100 13 0.96 (0.54, 1.72) 0.99 (0.55, 1.78) 
Other† 19 2 0.76 (0.17, 2.28) 0.72 (0.16, 3.13) 
*Use within 1 month before, but not within 12 weeks after conception as compared to no use of a hormonal contraceptive within the discrete 
categories of within12, 4, and 1 month before conception and within 12 weeks after conception 
**Adjusted for maternal age, maternal smoking at 17 weeks gestation, maternal pre-pregnancy BMI, and parity 







Table S4.9. Association between hormonal contraceptive use within 4 months prior to conception* and 
offspring overweight or obese by progestin type 
Exposure  Exposed (n) Overweight/obese (n) Crude OR (95% CI) Adjusted** OR (95% CI) 
None 9,987 1,342 referent referent 
Combination OC         
drospirenone and EE 544 58 0.77 (0.58, 1.01) 0.80 (0.60, 1.06) 
levonorgestrel and EE 1,001 137 1.02 (0.84, 1.24) 1.06 (0.88, 1.29) 
norethisterone and EE 136 20 1.11 (0.69, 1.79) 1.19 (0.73, 1.92) 
Progestin-only OC         
desogestrel 374 43 0.84 (0.61, 1.16) 0.83 (0.60, 1.16) 
norethisterone 201 32 1.22 (0.83, 1.79) 1.19 (0.81, 1.75) 
Vaginal ring         
etonogestrel and EE 153 15 0.70 (0.41, 1.20) 0.73 (0.43, 1.25) 
Other† 235 23 0.70 (0.45, 1.08) 0.71 (0.46, 1.10) 
*Use within 4 months before, but not within 1 month before and 12 weeks after conception as compared to no use of a hormonal 
contraceptive within the discrete categories of within12, 4, and 1 month before conception and within 12 weeks after conception 
**Adjusted for maternal age, maternal smoking at 17 weeks gestation, maternal pre-pregnancy BMI, and parity 






Table S4.10. Association between hormonal contraceptive use within 12 months prior to conception* and 
offspring overweight or obese by progestin type 
Exposure  Exposed (n) Overweight/obese (n) Crude OR (95% CI) Adjusted** OR (95% CI) 
None 9,987 1,342 referent referent 
Combination OC         
desogestrel and EE 101 13 0.95 (0.53, 1.71) 1.01 (0.56, 1.83) 
drospirenone and EE 685 77 0.82 (0.64, 1.04) 0.86 (0.67, 1.11) 
levonorgestrel and EE 1,267 154 0.89 (0.75, 1.07) 0.95 (0.79, 1.04) 
norethisterone and EE 159 33 1.69 (1.15, 2.48) 1.78 (1.22, 2.62) 
Progestin-only OC         
desogestrel 462 67 1.09 (0.84, 1.42) 1.07 (0.82, 1.39) 
norethisterone 279 44 1.21 (0.87, 1.67) 1.18 (0.85, 1.65) 
Vaginal ring         
etonogestrel and EE 204 21 0.74 (0.47, 1.16) 0.77 (0.49, 1.22) 
Transdermal     
norelgestromin and EE 118 15 0.94 (0.54, 1.62) 1.01 (0.58, 1.74) 
Injectable     
medroxyprogesterone 65 10 1.17 (0.60, 2.30) 1.14 (0.57, 2.25) 
Other† 117 15 0.95 (0.55, 1.63) 0.89 (0.52, 1.54) 
*Use within 12 months before, but not within 4 and 1 month before and 12 weeks after conception as compared to no use of a hormonal 
contraceptive within the discrete categories of within12, 4, and 1 month before conception and within 12 weeks after conception 
**Adjusted for maternal age, maternal smoking at 17 weeks gestation, maternal pre-pregnancy BMI, and parity 












Within 1  
month* 









 adjusted OR** 
(95% CI) 
 adjusted OR** 
(95% CI) 
None referent referent referent referent 
Combination OC 0.85 (0.66, 1.11) 1.06 (0.96, 1.17) 0.99 (0.85, 1.15) 0.99 (0.87, 1.14) 
Progestin-only OC 1.27 (0.69, 2.33) 1.04 (0.84, 1.29) 1.06 (0.84, 1.35) 1.16 (0.92, 1.46) 
Vaginal ring ‡ 0.72 (0.45, 1.13) 0.82 (0.56, 1.21) 0.87 (0.60, 1.17) 
Transdermal 
‡ 
0.99 (0.57, 1.72) ‡ 1.00 (0.61, 1.64)  
Injectable ‡ ‡ ‡ 1.04 (0.66, 1.65) 
Other† 0.87 (0.52, 1.45) ‡ 0.86 (0.17, 4.22) 0.75 (0.34, 1.64) 
*Represents discrete categories of exposure based on the last possible date of use as derived from date of prescription and the defined daily 
doses prescribed as compared to no use of a hormonal contraceptive within 12, 4, and 1 month of conception and with 12 weeks after 
conception 
**Adjusted for maternal age, maternal smoking at 17 weeks gestation, maternal pre-pregnancy BMI, and parity 
†Hormonal contraceptive types with <10 exposed cases collapsed into a single "other" category 







Table S4.12. Sensitivity analyses employing inverse probability weighting-GEE models  
  Early pregnancy* Within 1 month* Within 4 months* Within 12 months* 
Exposure  
adjusted OR**  
(95% CI) 
adjusted OR**  
(95% CI) 
 adjusted OR**  
(95% CI) 
 adjusted OR**  
(95% CI) 
None referent referent referent referent 
Combination OC 0.68 (0.47, 0.99) 1.04 (0.98, 1.21) 0.97 (0.82, 1.04) 0.99 (0.89, 1.15) 
Progestin-only OC 1.16 (0.72, 1.86) 1.00 (0.78, 1.29) 0.99 (0.77, 1.27) 1.10 (0.90, 1.36) 
Vaginal ring ‡ 0.60 (0.34, 1.04) 0.67 (0.46, 0.97) 0.77 (0.49, 1.23) 
Transdermal ‡ 1.06 (0.57, 1.94) ‡ 1.02 (0.59, 1.77) 
Injectable ‡ ‡ ‡ 1.06 (0.53, 2.12) 
Other† 0.86 (0.38, 1.96) ‡ 0.64 (0.34, 1.21) 0.58 (0.23, 1.46) 
*Represents discrete categories of exposure based on the last possible date of use as derived from date of prescription and the defined 
daily doses prescribed as compared to no use of a hormonal contraceptive within 12, 4, and 1 month of conception and with 12 weeks after 
conception 
**Adjusted for maternal age, maternal smoking at 17 weeks gestation, maternal pre-pregnancy BMI, and parity 
†Hormonal contraceptive types with <10 exposed cases collapsed into a single "other" category 
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